Coronary artery disease

Coronary artery disease (CAD) is the most common form of cardiovascular disease and refers to the narrowing or blockage of the coronary arteries, the vessels that supply oxygen-rich blood to the heart muscle. Its principal cause is atherosclerosis, a slow buildup of lipid-rich plaque in the arterial wall. When the heart's oxygen demand exceeds what narrowed vessels can deliver, the result is ischemia that can present as chest discomfort, shortness of breath, or, when a plaque ruptures and triggers a clot, a heart attack. CAD is closely tied to cholesterol metabolism, hypertension, diabetes, smoking, and inherited susceptibility, and it has been among the leading causes of death worldwide for decades.

This entry explains the disease in the order a clinician or student would encounter it. It begins with the anatomy of the coronary circulation and the cellular process of atherosclerosis, then reviews risk factors and the two broad clinical families, chronic coronary syndromes and acute coronary syndromes. It covers the non-obstructive and microvascular forms that complicate diagnosis, especially in women, and then the main diagnostic tools, including CT angiography, stress imaging, and invasive angiography. Treatment is split into medical therapy, drug treatment for lipids, antiplatelet effects and symptoms, and revascularization by stenting or bypass surgery, with a separate account of emergency reperfusion. The final sections address complications and prognosis, secondary prevention, global epidemiology and social disparities, the history of the field, and the questions that remain contested, such as the best revascularization strategy for stable multivessel disease.

Because the disease is measured in populations as well as in individual patients, the entry also draws on epidemiological evidence and public health strategy. Recent guideline revisions, including updated lipid targets and wider use of coronary artery calcium scoring and lipoprotein(a) testing, show that understanding and management are still changing, and the entry notes where evidence is strong and where it is still debated.

Definition and the coronary circulation

Coronary artery disease (CAD) refers to a reduction in blood flow through the coronary arteries that leaves heart muscle short of oxygen, a state called myocardial ischemia. The reduction can be obstructive, meaning a fixed narrowing or blockage of an epicardial vessel, most often from atherosclerotic plaque. It can also be functional, meaning the vessel is structurally open but fails to dilate or constricts abnormally, as in microvascular dysfunction or coronary vasospasm. Both forms cause ischemia, and the distinction matters because the mechanisms, diagnostic tests and treatments differ.

CAD is one cause of cardiomyopathy, a disorder of the myocardium itself. When CAD has damaged enough muscle to weaken the ventricle, the condition is usually labelled ischemic cardiomyopathy. Other cardiomyopathies, such as inherited, toxic, inflammatory or peripartum forms, involve no coronary obstruction and are classified separately. Clinicians therefore check coronary anatomy and perfusion before attributing a cardiomyopathy to a non-ischemic cause.

The coronary arteries and their territories

The two coronary arteries arise from the sinuses behind the aortic valve cusps, the left from the left cusp and the right from the right. The left coronary artery begins as a short left main trunk, which usually divides into the left anterior descending artery (LAD) and the left circumflex artery (LCx). The LAD runs down the anterior interventricular groove and supplies most of the anterior left ventricle and, through its septal branches, the front of the interventricular septum. The LCx runs in the atrioventricular groove and feeds the lateral wall of the left ventricle through its obtuse marginal branches. Occasionally a third branch, the ramus intermedius, arises between the LAD and LCx.

The right coronary artery (RCA) passes through the right atrioventricular groove and supplies the right atrium and right ventricle. It also reaches the sinoatrial node in most people and the atrioventricular node in a large majority, which is why RCA occlusion can cause conduction disturbances. Which vessel gives rise to the posterior descending artery defines coronary dominance. In most people this is the RCA (right dominance, roughly 70–85% depending on the series), while left dominance and codominance are less common. Dominance therefore determines whether the LCx or the RCA supplies the inferior wall and the posterior septum.

Diastolic perfusion and the oxygen balance

The left ventricle receives most of its blood flow during diastole. During systole, contracting muscle compresses the intramural vessels, so flow through the subendocardial layers falls sharply or stops. Left-sided pressures are much higher than right-sided ones, which makes this systolic compression more pronounced for the left ventricle and gives the left coronary territory a larger share of its flow in diastole. Anything that shortens diastole, such as a fast heart rate, or that raises diastolic pressure beyond the aortic root's ability to drive flow, can therefore reduce subendocardial perfusion.

The myocardium already extracts a large fraction of the oxygen delivered to it at rest, so it cannot respond to higher demand by extracting more. Instead it must raise coronary blood flow. Oxygen supply is the product of flow and arterial oxygen content, which depends largely on hemoglobin concentration and saturation. Demand is set mainly by heart rate, contractility and wall tension, which in turn depend on pressure and volume load. Ischemia occurs when demand rises faster than the coronary circulation can increase flow. Normally, vasodilation can increase flow several-fold above resting levels, a margin known as coronary flow reserve. A fixed stenosis reduces this margin, so ischemia first appears during exertion, when demand is high, and the resting supply may still be adequate.

Collateral circulation

The coronary arteries are linked by a network of small connecting vessels, which act as collaterals. Some are intracoronary, joining branches of the same artery, and others are intercoronary, joining branches of different arteries. In people without obstructive disease, these native channels are already present, and Seiler and colleagues estimated that in about one fifth to one quarter of individuals they can prevent ischemia during a brief occlusion. Their caliber depends on heart rate and blood pressure, and it varies widely between individuals.

When an artery narrows gradually rather than suddenly, the collateral vessels enlarge through arteriogenesis, a process driven by pressure gradients and increased wall shear stress. Enlarged collaterals can carry flow equal to roughly a fifth to a quarter of the normal flow through the open vessel, enough in many cases to limit infarct size. Experimental work in pigs showed that collaterals form earlier and more extensively when the RCA is occluded slowly than when the LAD is, which has been linked to differences in ventricular pressure and mass. Collaterals are not static, however. They can divert flow away from the territory they were meant to protect when the donor artery's own pressure falls, a phenomenon known as collateral steal, and they can regress after the occluded artery is reopened.

Atherosclerotic pathogenesis

Early lesion formation

Lesions appear to begin where the endothelium stops working normally. In susceptible arterial segments, reduced expression of eNOS and SOD compromises endothelial barrier integrity, and the fatty streak phase begins with dysfunctional endothelial cells and retention of apoB-containing lipoproteins in the subendothelial space. Once trapped, LDL is chemically modified, and oxidation is the most important change. Modified LDL induces endothelial cells to secrete several cytokines, including monocyte chemotactic protein-1 (MCP-1) and monocyte colony-stimulating factor (M-CSF). These signals draw in circulating monocytes. Monocytes adhere to the intima and differentiate into macrophages, which consume oxidized LDL to form large lipid-laden foam cells, and the accumulation of these cells constitutes an early plaque. Endothelial activation also amplifies this process by recruiting other immune cells and promoting further oxidation, so the lesion becomes self-sustaining as an inflammatory process.

Plaque architecture and remodeling

As lesions advance, a necrotic core may develop, consisting of lipids, foam cells, cell debris, and cholesterol crystals. The core is separated from flowing blood by a cap of collagen and elastin that gives the plaque its mechanical strength. Smooth muscle cell secretions of proteoglycans, collagens, and elastin further add to plaque mass. Persistent lipid elevation favors plaques with a large necrotic core and a thin cap, which are the most rupture-prone form. Calcification becomes prominent in older lesions: stenotic lesions tend to have smaller lipid cores, more fibrosis and calcification, thick fibrous caps, and less compensatory enlargement.

Plaques often grow outward before they narrow the lumen. Expansive, or outward, vascular remodeling allows the arterial wall to accommodate a growing lesion while the channel remains open. Lesions that finally produce significant luminal narrowing typically lack this compensatory enlargement, which is one reason angiographic stenosis is a late and incomplete marker of plaque burden.

Rupture and erosion as triggers of thrombosis

Plaque rupture and erosion are the two most common mechanisms for acute coronary syndromes. In rupture, a thin cap tears and exposes a thrombogenic core. Lesions rich in tissue factor and inflammatory mediators generate large amounts of thrombin when they rupture, producing fibrin-rich occlusive thrombi, which typically cause STEMI. Erosion is different: it occurs without fibrous cap rupture, and the thrombus lies in direct contact with an intimal surface that lacks endothelial cells but is enriched in smooth muscle cells and proteoglycan matrix. Shear-stress gradients have been proposed to trigger this process through Toll-like receptor 2 signaling in endothelial cells, followed by neutrophil extracellular trap formation. Plaque erosion accounts for about one third of acute coronary syndromes and up to two thirds of non-STEMI.

Many events also arise from plaques that were not severely narrowed beforehand. Plaques that often, but not always, cause significant luminal stenosis are characterized by a degraded cap with organizing thrombus over a necrotic core, which is the thin-cap fibroatheroma. Because such lesions can look benign on angiography, the severity of a stenosis is a poor proxy for the risk of an acute event.

Smooth muscle cells, platelets, and matrix degradation

Smooth muscle cells shape the balance between plaque growth and stability. Platelet-derived growth factor is considered the dominant chemoattractant that stimulates smooth muscle cell migration and mitosis during fibrous cap formation. These synthetic smooth muscle cells remodel the matrix and deposit a collagenous cap next to the endothelium, which forms a dense barrier against the release of thrombogenic plaque material. Loss of these cells, by contrast, can produce a fragile, rupture-prone fibrous cap.

Platelets are activated by the same lipid-driven environment. Oxidized LDL promotes endothelial dysfunction, foam cell formation, monocyte chemotaxis, smooth muscle cell proliferation and migration, and platelet activation, which together can culminate in plaque instability and rupture.

Matrix degradation links these processes. Prolonged inflammation within the plaque stimulates matrix metalloproteinases that break down extracellular matrix, and an imbalance between these enzymes and their inhibitors weakens the fibrous cap. A net increase in collagen breakdown leads to fibrous cap weakening and compensatory changes in vessel wall architecture.

Risk factors and their mechanisms

Non-modifiable and modifiable factors

Risk factors for coronary artery disease fall into two broad groups. Non-modifiable factors include age, sex, family history, and ancestry. Risk rises steeply with age, and men develop symptomatic disease earlier than premenopausal women, although the gap narrows after menopause (menopause). A family history of premature disease signals a shared genetic and environmental background, and genetic studies have identified common variants that influence lipid levels and vessel-wall biology (genetic architecture). Ancestry matters both biologically and socially: the classic risk factors have been shown to apply across racial and ethnic groups, but their distribution differs between populations.

Modifiable factors include high blood pressure, dyslipidemia, diabetes, excess body weight, tobacco use, physical inactivity, and an unhealthy diet. Each acts through partly distinct pathways. Hypertension mechanically stresses the arterial wall and promotes endothelial injury. Tobacco smoke introduces oxidants and impairs endothelial function. Inactivity and excess adiposity shift metabolism toward insulin resistance and an atherogenic lipid profile. Because these exposures frequently cluster in the same person, their effects on risk combine rather than appearing in isolation.

Lipids: LDL cholesterol, lipoprotein(a), triglycerides, and HDL

Apolipoprotein B-containing particles, principally LDL, carry cholesterol into the arterial intima, where they are retained by proteoglycans and become oxidized. Oxidized LDL is taken up by macrophages through scavenger receptors, producing foam cells and the lipid core of a plaque. Higher circulating LDL concentration increases the number of particles available for this process, which explains the consistent, graded relationship between LDL cholesterol and events.

Lipoprotein(a) adds a further, partly independent route. It consists of an LDL-like particle with the glycoprotein apolipoprotein(a) covalently attached to apolipoprotein B-100. Its apolipoprotein(a) component resembles plasminogen, so it may interfere with fibrinolysis and favor clot formation. Lp(a) also carries oxidized phospholipids that activate monocytes, stimulate endothelial adhesion molecules, and promote smooth muscle cell migration. Its plasma level is largely set by hepatic synthesis and is strongly determined by genotype, a feature that has supported causal interpretations of Lp(a) in genetic studies.

Triglycerides and high-density lipoprotein (HDL) influence risk through different mechanisms. Elevated triglycerides are carried mainly by triglyceride-rich remnant particles, which can enter the arterial wall and contribute to cholesterol deposition. Low HDL cholesterol is associated with reduced reverse cholesterol transport and weaker anti-inflammatory and antioxidant activity of the particle, although the exact causal weight of HDL levels remains debated.

Diabetes, chronic kidney disease, and inflammation

In diabetes, sustained hyperglycemia and insulin resistance damage the endothelium, increase oxidative stress, and promote glycation of proteins in the vessel wall. Diabetes is also accompanied by hypertriglyceridemia and small, dense LDL particles, which penetrate the intima more readily. Its effect on coronary risk is large enough that diabetes has been described as roughly doubling the risk of cardiovascular events in many cohorts.

Chronic kidney disease accelerates atherosclerosis through a combination of traditional and nontraditional mechanisms. Patients with reduced kidney function show higher rates of dyslipidemia, particularly triglyceride-enriched lipoproteins, and reduced particle size of LDL. Uremic toxins such as p-cresyl sulfate accumulate and promote vascular damage. Other contributors include vascular calcification, anemia, mineral metabolism disorders, volume overload, and persistent inflammation. In macrophages, CKD-associated changes can impair cholesterol efflux, and the inflammatory environment expands pro-atherogenic monocyte subsets. Mortality from cardiovascular causes is substantially higher in advanced CKD than in people with normal kidney function, and conventional risk scores such as the Framingham equation perform poorly in this group.

Chronic inflammatory conditions, including rheumatoid arthritis, psoriasis, and systemic lupus erythematosus, raise cardiovascular risk independently of traditional factors. Inflammatory cytokines such as TNF-α and IL-6 increase the expression of adhesion molecules and chemokines, which recruit leukocytes to the endothelium. Activated macrophages then sustain plaque growth and may destabilize fibrous caps.

Evidence from cohort studies

The Framingham Heart Study, begun in 1948 in Framingham, Massachusetts, is the foundational cohort for the modern risk-factor concept. Its early reports showed that high blood pressure and high cholesterol were associated with new heart disease within four years, and later analyses identified smoking, obesity, diabetes, and physical inactivity as additional major factors. The study also clarified the protective association of HDL, showing that low HDL is a risk marker alongside high LDL. Framingham investigators demonstrated that atherosclerosis is not an inevitable feature of aging and that blood pressure elevation carries risk in women and older adults. Multivariable models built from these cohorts allowed researchers to estimate individual risk by combining factors, and the approach was extended to other cohorts, including those with different ancestry.

Cohort data are observational, so associations are not automatically causal. Investigators addressed this by replicating findings across populations, testing for confounding, and later combining them with trials and Mendelian randomization approaches. Measures such as the odds ratio and relative risk quantify these associations, while attributable-risk estimates from population studies indicate how much disease could be prevented by modifying each factor.

Chronic coronary syndromes and angina

Chronic coronary syndromes as a spectrum

Guidelines use several overlapping names for this group, including chronic coronary syndromes (CCS), chronic CAD, and stable ischemic heart disease. The category is best read as a spectrum rather than one diagnosis. It spans patients with stable angina, people with an old infarction, and those whose disease is stable after revascularization by PCI or CABG (8-1). The term applies to disease during quiet periods, particularly those preceding or following an ACS, so a single patient may pass between stable and acute phases over the course of the disease.

Stable angina

Clinicians define stable angina by its reproducibility. The discomfort recurs at a consistent workload or emotional trigger and resolves with rest or nitroglycerin (1-5). The mechanism is a supply–demand mismatch: it most commonly results from fixed atherosclerotic narrowing of the coronary arteries. When heart rate, blood pressure, or contractility rises, flow cannot increase enough to meet the extra oxygen requirement (7-9).

Patients commonly describe a squeezing or heavy sensation behind the breastbone that may travel to the jaw, neck, shoulder, or left arm (3-5). Episodes usually last minutes and subside with rest or nitrates (3-6). Because the pattern stays the same from one episode to the next, it can be distinguished from unstable angina (3-7). The lesion is not acutely unstable. There is no plaque rupture, thrombosis, or necrosis (3-4). Severity is often graded with the Canadian Cardiovascular Society scale, which relates symptoms to the amount of activity needed to provoke them (22-1). For about half of people with coronary disease, stable angina is the first clinical sign; the others first come to attention through unstable angina, infarction, or sudden death (7-7).

Atypical presentations and silent ischemia

Many patients never report classic chest pain. Instead, they experience nonspecific symptoms such as dyspnea, diaphoresis, fatigue, belching, nausea, light-headedness, or indigestion that occur with exertion or stress. These symptoms are termed anginal equivalents (anginal equivalents). Dyspnea is the most common of them, and female patients and those with diabetes or chronic kidney disease are especially prone to such presentations (22-4,22-5). Breathlessness often reflects ischemia-induced ventricular dysfunction, since these symptoms are usually due to left ventricular systolic or diastolic dysfunction whenever the myocardium becomes ischemic under stress. Women may describe a vaguer, sometimes burning discomfort rather than pressure (19-2). In older adults, the same atypical pattern is common, and in acute settings up to 30% of elderly patients with ACS present without chest pain.

Silent myocardial ischemia is defined as objective evidence of myocardial ischemia in the absence of chest discomfort or other angina equivalents. It is detected with exercise electrocardiography, nuclear perfusion imaging, or echocardiography, and it is a particular concern in diabetes. Among people with diabetes, silent ischemia is prevalent in diabetic populations due to autonomic neuropathy, which can blunt the sensory signals that normally accompany ischemia. Reported prevalence varies widely: diabetics have shown varying prevalence rates of SMI (ranging from 20% to 50%) due to heterogeneity in research populations, screening methods, and risk factor profiles. In one North Indian cross-sectional study of asymptomatic patients with type 2 diabetes, SMI was detected in 18.31% (13/71) of participants. Predictors identified in studies include smoking, hypertension, dyslipidemia, diabetes duration over 10 years, and poor glycemic control, along with age, with a marked rise beyond the age of 55. Silent ischemia is also found in advanced kidney disease, where it is independently associated with age, diabetes mellitus, left ventricular hypertrophy, and elevated PTH levels.

Because symptoms may be absent, a patient without complaints can still have a prior infarction or ongoing ischemia that only objective testing reveals. The absence of pain therefore does not establish the absence of coronary disease, a point that matters for interpreting the diagnostic and risk assessments described elsewhere in this article.

Acute coronary syndromes: presentation and classification

Three clinical entities under one umbrella

Acute coronary syndrome (ACS) is a clinical umbrella rather than a single diagnosis. It covers unstable angina, NSTEMI and STEMI, all of which are presumed to arise from plaque rupture or erosion followed by thrombosis. Under the Universal Definition of MI, these events would be classified as type 1 MI events, which separates them from supply–demand mismatches and other causes of troponin rise. The dividing line between unstable angina and infarction is biochemical. In unstable angina, ischemia is transient and flow is reduced, but there is no significant myonecrosis detected by circulating troponin. Infarction is reserved for more prolonged or severe myocardial ischemia with raised markers of myocyte death. NSTEMI and STEMI differ from each other on the electrocardiogram, and the ECG is the first tool used to separate them.

Electrocardiographic and biomarker criteria

For NSTE-ACS, the ECG shows new or presumed new and usually dynamic horizontal or down-sloping ST-segment depression ≥0.5 mm in ≥2 contiguous leads and/or T-wave inversion >1 mm in ≥2 contiguous leads. STEMI requires new or presumed new ST-segment elevation of ≥1 mm in ≥2 anatomically contiguous leads (measured at the J-point), with higher thresholds in leads V2–V3 that depend on sex and age. Many NSTE-ACS patients have only nonspecific ST or T changes, or a normal tracing, and the absence of electrocardiographic evidence of ischemia does not exclude ACS. Posterior leads (V7–V9) are recommended when a left circumflex occlusion is suspected, especially with isolated ST depression in V1–V3. Because the presentation can change quickly, a single normal tracing is not sufficient to exclude ACS, and guidelines call for a serial 12-lead ECG when the first one is non-diagnostic. Clinical progression from unstable angina to NSTEMI and STEMI may be rapid during initial evaluation and treatment.

Cardiac troponin supplies the biomarker criterion. Troponin is released when cardiomyocytes are injured, and in acute infarction its concentration rises and then falls. Current US guidance favors high-sensitivity assays measured as early as possible and repeated after a few hours. A single value cannot distinguish acute injury from chronic elevation, which is common in chronic kidney disease, heart failure and other conditions. Serial sampling addresses this by looking for a dynamic change: a rise and fall pattern indicates acute injury, while a stable, persistently raised level points toward chronic myocardial stress. The rise-and-fall pattern does not, however, separate NSTEMI from STEMI, which is why the ECG remains essential for that distinction. Algorithms that combine measurements at 0 and 1 hour, as used in European practice, have been reported as the most sensitive single approach for detecting myocardial infarction, although they still miss some cases when used alone.

Typical symptoms

Classic presentations include a pressure-like or tight central chest discomfort that may radiate to the left arm, jaw, neck or back, often with sweating, nausea, vomiting or breathlessness. Symptoms of this kind are neither specific nor fully reliable, and they are less typical in older adults, people with diabetes and many women, which is why the ECG and troponin are interpreted alongside the history rather than in place of it. Symptom onset time also matters for treatment decisions in STEMI, where reperfusion is time-sensitive.

Risk scores and the timing of invasive evaluation

Risk scores are used to estimate short-term danger and to decide how quickly a patient needs angiography. The GRACE score is the most widely used tool for NSTE-ACS. The GRACE 2.0 version estimates risk of in-hospital, 6-mo, 1-y, 3-y, death or death/MI, while the TIMI scores for unstable angina/NSTEMI and STEMI target shorter horizons, 14-d all-cause death, MI, or urgent revascularization and 30-d all-cause death, respectively.

For timing, a GRACE score above 140 defines high ischemic risk, and the ESC 2023 and ACC/AHA 2025 acute coronary syndrome guidelines support the use of the GRACE score to identify high-risk patients for an early invasive strategy. In a predefined VERDICT subgroup, the benefit of early angiography appeared in the high-risk tertile but not in the lower-risk patients. Different GRACE variants, however, reclassify patients considerably; in one comparison up to 63.8% of participants were reclassified into a different risk category. In STEMI, the score should not delay reperfusion; it is used mainly for prognosis.

Non-obstructive and microvascular disease

Some patients with chest pain, ischemic ECG changes or troponin rises have no flow-limiting narrowing on coronary angiography. Two terms describe this group. INOCA is defined as angina or ischemia with less than 50% epicardial coronary artery stenosis on angiography. MINOCA is an acute myocardial infarction in which cardiac troponin rises or falls above the 99th percentile on serial measurement, with less than 50% epicardial stenosis. Roughly half of patients with signs and symptoms suggestive of myocardial ischemia do not have an obstructive, flow-limiting stenosis.

Mechanisms: microvascular dysfunction and vasospasm

The two main mechanisms are coronary microvascular dysfunction and coronary vasospasm, and they can coexist. Microvascular dysfunction may reflect vasomotor dysregulation and structural remodeling of the arterioles, which cannot be seen on angiography. Structural forms involve arteriolar remodeling, capillary rarefaction, or fibrosis, while functional forms involve impaired vasodilation or paradoxical vasoconstriction at the microvascular level. Vasospasm can affect the epicardial arteries or the arterioles. Classic vasospastic angina, also called Prinzmetal angina, produces recurrent chest pain that responds to nitrates, whereas the more common pattern involves distal, diffuse subtotal epicardial vasospasm, characterised by ST segment depression, which may occur during physical exertion. Spasm was once regarded as a condition mainly of middle-aged men in East Asia, but more recent data suggest that it may be a common cause of MINOCA in European and North American patients, with a more equal sex distribution.

MINOCA has a broader differential. Besides vasospasm and microvascular dysfunction, the mechanisms include coronary plaque disruption, thromboembolism, and spontaneous coronary artery dissection. Elevated troponin in women may also reflect non-ischemic causes such as myocarditis, nonischemic cardiomyopathy, and Takotsubo syndrome. Estimates of prevalence vary between sources. One review puts INOCA at 3–4 million individuals with a female predominance, while a meta-analysis of MINOCA found a higher prevalence in men (61%), so the sex distribution depends on the population studied.

Spontaneous coronary artery dissection

Spontaneous coronary artery dissection (SCAD) is a separate, non-atherosclerotic cause of acute coronary events. Dissection involves separation of the arterial layers, which creates a false lumen that impairs blood flow. The intramural hematoma or intimal tear is thought to arise spontaneously. Its incidence on angiographic series is 0.28 to 1.1%, and most patients are young, otherwise healthy women, about 30% of whom are in the postpartum period. Recent data suggest that the condition affects young women with few or no cardiovascular risk factors, although hormonal status does not appear to be a favourable factor. Proposed triggers include hormonal, hemodynamic and autoimmune changes that are common in pregnancy, but these remain hypotheses. Presentations range widely, from no symptoms to typical angina and sudden cardiac death, so the incidence is probably underestimated. Because the optimal treatment of SCAD has not yet been established, management is usually individualized.

Diagnosis by physiology rather than anatomy

Invasive coronary function testing has changed how these conditions are identified. Intracoronary acetylcholine provocation was first described in the 1980s to diagnose coronary artery spasm, but only in recent years have American and European guidelines recommended invasive coronary function testing for patients with angina and non-obstructive arteries. A positive test is generally defined by reproduction of symptoms with ischemic ECG changes, and by the vessel diameter response. Microvascular function is assessed with pressure-wire indices: a coronary flow reserve below 2.0 and/or an index of microcirculatory resistance of 25 or more is diagnosed as coronary microvascular dysfunction. The sequence of testing is contested. Because nitroglycerin given before acetylcholine can mask spasm, one rechallenge study found that only 55% of patients redemonstrated epicardial spasm after nitroglycerin, which is why some centres test for spasm first and others measure microvascular resistance first.

These conditions are under-recognised for several reasons. Symptoms are often typically under-recognised or misdiagnosed, despite their association with morbidity, impaired quality of life and future healthcare resource use. The tests require specialist expertise, so the diagnosis is frequently missed. A clear angiogram was traditionally read as reassurance, and the implication that chest pain with a normal angiogram had a non-cardiac cause persisted. Over time, the field has moved toward physiology-based assessment, which can identify the mechanism and direct specific therapy, such as calcium channel blockers for vasospasm.

Diagnostic testing

Because coronary artery disease often produces no symptoms until late, and because symptoms are unreliable indicators of it, diagnosis relies on a sequence of tests. Each test answers a different question: whether the heart's electrical activity or wall motion shows signs of ischemia, whether blood flow is reduced under stress, or whether the coronary arteries themselves are narrowed.

Resting electrocardiography

The resting electrocardiogram (ECG) is the first test in most patients with suspected disease. It is cheap and quick, and it can reveal Q waves from a previous infarction, ST-segment or T-wave changes, and arrhythmias. Its limits are substantial. Many patients with significant coronary stenoses have a completely normal resting tracing, and conduction abnormalities such as left bundle branch block or left ventricular hypertrophy can obscure ischemic changes. A normal ECG therefore lowers the probability of an acute event but does not exclude chronic obstructive disease, and it cannot establish the anatomical cause of symptoms.

Stress testing and inducible ischemia

Stress tests are used to provoke ischemia and detect it while the heart is working harder. Exercise is preferred when the patient can perform it, with ECG monitoring for ST-segment depression. When exercise is not possible, or when the resting ECG is uninterpretable, a pharmacological agent such as adenosine, regadenoson, or dobutamine is given to induce stress. Imaging is then added to improve sensitivity and localization:

• Stress echocardiography looks for new regional wall-motion abnormalities, which appear when a territory becomes ischemic. It is inexpensive, radiation-free, and widely available, but its image quality depends on the operator and on the patient's acoustic window.
• Nuclear perfusion imaging (single-photon emission computed tomography or positron emission tomography, using tracers such as technetium-99m or rubidium-82) detects reduced myocardial blood flow as a perfusion defect. Positron emission tomography is generally more precise for quantifying flow, while single-photon emission imaging is more widely used.
• Stress cardiac magnetic resonance combines perfusion imaging with myocardial tissue characterization, so it can also show scarring or viability within the same examination, and it avoids ionizing radiation. Availability and the need for breath-holding are practical constraints.

Each modality shows whether ischemia is present and how much myocardium is affected, but none of them directly shows the lesion that causes it. A positive stress test therefore usually leads to further anatomical or invasive evaluation, and a negative test in a patient with high pretest probability is interpreted cautiously.

Coronary CT angiography

Coronary computed tomography angiography (CCTA) uses contrast-enhanced computed tomography to visualize the coronary arteries, plaque, and calcification directly. Its main strength is its negative predictive value. In a 2025 systematic review and Bayesian meta-analysis of 27 studies comparing CCTA with invasive angiography, the pooled sensitivity for anatomically significant disease was 0.94, while specificity was moderate at 0.73, and the authors concluded that the test performs well for ruling disease out in low- to intermediate-risk patients without prior coronary intervention. Its weaknesses are the false-positive results caused by heavy calcification and blooming artifacts, and the reduced reliability in patients with stents or bypass grafts, in whom positive findings often need confirmation. Image quality also depends on heart rate and rhythm.

The clinical case for CCTA rests mainly on the SCOT-HEART randomized trial, which enrolled 4,146 patients with suspected stable angina referred to cardiology clinics in Scotland. Adding CCTA to standard care changed the diagnosis in roughly a quarter of participants, and at five years it was associated with fewer deaths from coronary heart disease or non-fatal myocardial infarction, without a significant increase in invasive angiography. A ten-year follow-up reported a persisting reduction in that composite endpoint. Because many participants had normal coronary arteries, the trial also showed that anatomical imaging can reassure as well as reveal disease.

Invasive coronary angiography and fractional flow reserve

Invasive coronary angiography, performed by injecting contrast through catheters placed in the coronary ostia, remains the reference standard for coronary anatomy. It shows the location and apparent severity of stenoses, but angiographic severity correlates imperfectly with how much a lesion limits blood flow. A moderate narrowing can be harmless, while an apparently modest one can be the main cause of ischemia when it sits in a critical position.

Fractional flow reserve (FFR) addresses this gap. A pressure wire is passed across the lesion, and the ratio of distal to proximal coronary pressure is measured during maximal hyperemia, usually induced with intravenous adenosine. A value of 0.80 or less is conventionally taken to indicate that the stenosis is hemodynamically significant. In the FAME trial, which randomized patients with multivessel disease, FFR-guided percutaneous intervention reduced major adverse cardiac events at two years compared with angiography-guided treatment, largely by reducing the number of stents placed. By five years, the event rates in the two groups had converged, although the FFR-guided group had received fewer stents and used fewer resources. Physiology-guided decisions can therefore change management in both directions: lesions that look severe but have normal FFR can be left untreated, and lesions that look moderate but have low FFR can be treated. Related physiological indices, such as the instantaneous wave-free ratio, are used for similar decisions with a resting rather than hyperemic measurement.

Risk assessment and screening

Long-term risk equations

Estimating the risk of people without established disease relies on sex-specific prediction models. The American Heart Association and the American College of Cardiology developed the pooled cohort equations (PCEs) in 2013. They are sex- and race-stratified models that estimate risk of ASCVD. The AHA's PREVENT equations, released in 2023, were built to update them. The PREVENT equations use a larger, more contemporary, and diverse U.S. dataset than the Pooled Cohort Equations. The main differences are these:

• Age range: PREVENT enables risk calculation across a wider age range (30–79 versus 45–79 years old for the PCE).
• Outcomes: PREVENT estimates separate outcome-specific 10-year and 30-year risk estimates for total cardiovascular disease, atherosclerotic cardiovascular disease, and heart failure. The PCEs address ASCVD alone.
• Predictors: PREVENT is race-free and incorporates kidney function and BMI as predictors, and optional inputs include urine albumin-creatinine ratio, hemoglobin A1c, and social deprivation index.

Calibration is the other point of comparison. One independent summary reported that the slope of observed to predicted risk was close to 1 for PREVENT and ranged from 0.50 to 0.54 for PCE for ASCVD, which implies that the older model overestimated risk substantially. The value of the 30-year estimate lies mainly in younger adults with low 10-year risk, who have one or more risk factors but a low 10-year risk. No formal cutoffs or thresholds have been established to define high 30-year risk in current guidance for total CVD.

Coronary artery calcium scoring

Coronary artery calcium (CAC) is a marker of subclinical calcified atherosclerosis. Agatston et al. first described noncontrast-enhanced, electrocardiographically gated computed tomography as an effective tool to quantify CAC in 1990. The Agatston score is a weighted sum of calcified lesion area across the coronary arteries, expressed in Agatston units, so a score of zero means no detectable calcium. The score is most often used in people aged 40 to 75 with intermediate estimated risk. The 2018 ACC/AHA guideline defined intermediate 10-year ASCVD risk as 7.5% to 19.9%, and it used the score to decide whether to start or defer statins. A score of zero may justify delaying therapy, though statin therapy should be withheld or delayed unless the patient is a cigarette smoker, has diabetes, or has a strong family history of premature ASCVD. A score of 1 to 99 favors treatment in older patients, and a score of 100 or more supports starting a statin.

Evidence on the score's value remains contested. Reviews report that CAC offers superior prognostic value compared to traditional risk estimators such as the Framingham Risk Score and pooled cohort equations. The USPSTF reached a different conclusion, finding insufficient evidence that adding the CAC score to traditional risk assessment improves patient-oriented outcomes. Calcium testing is less informative at the extremes of traditional risk. It is less informative in patients deemed low- or high-risk based on traditional risk scores, which is why it is generally reserved for selected patients whose treatment decisions are unclear.

Lipoprotein(a) measurement

Lipoprotein(a) [Lp(a)] is a unique apolipoprotein B (ApoB)-containing lipoprotein, similar to low-density lipoproteins (LDL). Its concentration is set largely by inheritance, and lifestyle changes have little impact on Lp(a) levels, and they remain relatively stable throughout life. Risk rises in a graded way with concentration, and thresholds used by different bodies vary. For example, one consensus treats measurements ≥125 nmol/L (≥50 mg/dL) as levels suggesting high risk. Some researchers have also documented that Lp(a) shows substantially higher real-world intraindividual variability than previously assumed, which can reclassify some patients over time.

Recommendations on testing have shifted toward universal measurement. The 2019 ESC/EAS guideline advised that Lp(a) measurement should be considered at least once in each adult person's lifetime. In 2026, the ACC/AHA dyslipidemia guideline recommends that all adults have their Lp(a) level measured at least once. Because drugs to specifically and effectively lower Lp(a) are not yet available, the main clinical value of the result is to identify risk and to prompt control of other modifiable factors. Its heritability also supports cascade screening of family members.

Trade-offs of screening

Every screening test has to be weighed against its positive predictive value, which depends on pretest probability. In a population with low disease prevalence, even a test with good sensitivity and specificity generates many false positives. Broad screening therefore carries a risk of overdiagnosis: incidental findings may prompt further testing, anxiety, or treatment that brings little benefit, particularly among people whose absolute risk is low. Conversely, a test restricted to people already at high risk may miss those whose risk is underestimated by conventional tools. For this reason, screening decisions usually combine a validated risk estimate, a biomarker or imaging result, and a discussion of the patient's preferences, rather than treating any single test as decisive. Routine computed tomography screening also involves radiation exposure, which adds to the balance of benefit and harm.

Pharmacological management

Statins and LDL-cholesterol targets

Statins inhibit HMG-CoA reductase, the rate-limiting enzyme of cholesterol synthesis in the liver. Lower intrahepatic cholesterol increases expression of LDL receptors, so more LDL cholesterol is cleared from the blood. Regimens are classed by intensity: high-intensity agents (such as atorvastatin 40–80 mg or rosuvastatin 20–40 mg) typically lower LDL-C by about half or more, and moderate-intensity agents by roughly 30–49%. Principal adverse effects are muscle symptoms, a small increase in new-onset diabetes, and, rarely, rhabdomyolysis.

Target levels have changed across guideline cycles. The 2026 ACC/AHA multisociety dyslipidemia guideline returned to absolute goals after a period focused on percentage reduction. For patients with clinical ASCVD who are very high risk, the LDL-C goal is below 55 mg/dL and the non-HDL-C goal below 85 mg/dL. Other patients with ASCVD are aimed at LDL-C below 70 mg/dL, and primary-prevention patients with a 10-year PREVENT risk of at least 10% share that <70 mg/dL threshold. Borderline and intermediate-risk adults are aimed at LDL-C below 100 mg/dL. Where persistent LDL-C remains at or above 70 mg/dL on maximally tolerated statin, the guideline suggests adding ezetimibe or a PCSK9 inhibitor. The European position differs in detail. The 2025 ESC/EAS focused update kept the 2019 targets, including LDL-C below 55 mg/dL for very high-risk patients, and proposed a threshold below 40 mg/dL (class IIb) for extreme-risk patients with recurrent events on maximal therapy or polyvascular atherosclerosis. It also favours early combination therapy, not a stepwise approach.

Non-statin lipid-lowering agents

Ezetimibe blocks the NPC1L1 transporter in the intestinal wall, reducing absorption of dietary and biliary cholesterol. It adds a further reduction of roughly 20–25% in LDL-C when combined with a statin and is available as an inexpensive generic. In the IMPROVE-IT trial after acute coronary syndrome, adding ezetimibe to simvastatin produced a modest but significant reduction in major cardiovascular events compared with simvastatin alone.

PCSK9 monoclonal antibodies, such as evolocumab and alirocumab, bind circulating PCSK9. Normally PCSK9 promotes degradation of the LDL receptor; blocking it allows receptors to recycle and clear more LDL particles. These agents usually reduce LDL-C by about 50–60% on top of statin therapy and are given by subcutaneous injection every two to four weeks. The FOURIER and ODYSSEY OUTCOMES randomized trials showed fewer major cardiovascular events in patients with established disease. Because they are costly, their use is often restricted to high-risk patients who cannot reach their targets with statins and ezetimibe. The 2025 ESC/EAS update also added bempedoic acid to the non-statin options.

Antiplatelet therapy

Aspirin irreversibly acetylates cyclooxygenase-1 in platelets, which blocks thromboxane A2 production and suppresses aggregation for the platelet's lifespan. Low daily doses, usually 75–100 mg, are used for secondary prevention. P2Y12 inhibitors block the ADP receptor on platelets. Clopidogrel is a prodrug activated by hepatic CYP2C19, so its effect varies between patients. Prasugrel acts faster and more strongly but raises bleeding risk and is avoided in patients with a history of stroke or transient ischaemic attack. Ticagrelor binds reversibly, is more potent than clopidogrel, and is associated with dyspnoea.

Dual antiplatelet therapy (DAPT) combines aspirin with a P2Y12 inhibitor. It is used after stent placement because the stent surface, before complete endothelialisation, is thrombogenic, and because thrombosis is a leading cause of early stent failure. After acute coronary syndromes, the thrombus arises from plaque rupture or erosion, so the drugs also address this process. The default duration is 12 months after PCI for acute coronary syndrome, according to the American guidance, while European guidance uses 6 months after drug-eluting stent placement in chronic coronary syndromes, followed by long-term aspirin. Shorter courses of one to three months, followed by P2Y12 monotherapy, are permitted for patients at high bleeding risk, and ticagrelor monotherapy after about three months is an option in selected low-ischaemic-risk patients with acute coronary syndrome. Recent trials such as STOPDAPT-2 have supported shorter regimens, and the optimal duration remains debated.

Anti-anginal and antiischemic drugs

Beta blockers antagonise β1-adrenergic receptors in the heart. They reduce heart rate, contractility and blood pressure, which lowers myocardial oxygen demand, and they lengthen diastole, which increases time for coronary perfusion. They are usually first-line for stable angina and are also used after myocardial infarction with reduced ejection fraction and in heart failure. Caution is needed in asthma, bradycardia and heart block, and abrupt withdrawal can provoke rebound ischaemia. Whether long-term beta blockade benefits patients with preserved ejection fraction after infarction is now contested.

Calcium channel blockers fall into two groups. Dihydropyridines, such as amlodipine and nifedipine, mainly dilate arterioles, lowering afterload and blood pressure, and relieve coronary vasospasm. Non-dihydropyridines, verapamil and diltiazem, slow atrioventricular conduction and reduce heart rate and contractility, and they should be avoided in heart failure with reduced ejection fraction. Dihydropyridines are the preferred agents for vasospastic angina.

Nitrates, typically nitroglycerin, release nitric oxide, which activates guanylate cyclase and raises cyclic GMP in smooth muscle. The resulting relaxation dilates veins, reducing preload and wall tension, and dilates coronary arteries. Sublingual or spray nitroglycerin relieves acute angina within minutes, while long-acting isosorbide mononitrate or dinitrate is used for prevention, with a nitrate-free interval to limit tolerance. Headache is common. Nitrates are contraindicated with phosphodiesterase-5 inhibitors such as sildenafil, which can cause dangerous hypotension, and they should be used cautiously in severe hypotension or right ventricular infarction.

Ranolazine inhibits the late inward sodium current in cardiomyocytes. Reducing sodium overload limits calcium accumulation through the sodium–calcium exchanger, which lowers diastolic wall tension and improves relaxation. It relieves angina without meaningful effects on heart rate or blood pressure, so it is useful as add-on therapy or when beta blockers or calcium channel blockers are poorly tolerated. Its main cautions are QT prolongation, interactions with CYP3A and P-glycoprotein substrates and inhibitors, the need to limit metformin doses, and contraindication in liver disease.

Coronary revascularization

Percutaneous coronary intervention

Catheter-based treatment of coronary narrowing began with a balloon. Andreas Grüntzig's first human coronary dilatation, performed at the University Hospital of Zurich in mid-September 1977, followed a series of canine experiments and marked the first of many successful angioplasty cases and the birth of a new field. Before this, the primary treatment for CAD was coronary artery bypass grafting (CABG), a highly invasive surgical procedure. A balloon inflated inside the lesion presses the accumulated plaque outward to restore flow to allow increased blood flow.

Plain balloon dilatation was limited by abrupt closure and restenosis. Metal stents, first implanted in humans in 1986, addressed the first problem by scaffolding the vessel. Restenosis rates were improved and reduced by approximately 30% compared with conventional PTCA, but the problem was not eliminated. Stents prevented the elastic recoil of the treated segment, yet the neointimal growth response to vessel injury was, in some analyses, more pronounced in stented segments Stents worked by preventing recoil compared with conventional PTCA, which showed that neointimal hyperplasia was even increased.

Drug-eluting stents (DES) addressed this growth response. A polymer coating allows controlled release of therapeutic agents at the site of injury, most commonly sirolimus or paclitaxel. These agents blunt the proliferation of cells that thicken the wall after injury. In the pivotal SIRIUS trial, at two years, target lesion revascularization was 5.8% in the drug-eluting stent arm versus 21.3% in the bare metal stent arm. Across the field, the incidence of in-stent restenosis fell to 5–10%, compared with the bare-metal era when up to a third of patients presented with restenosis. Restenosis remains more frequent in patients with diabetes, in whom stenting has reduced but not closed the gap with other patients diabetic patients continue to have significantly higher restenosis rates and clinical events following PCI.

Coronary artery bypass grafting

CABG creates a detour around a stenosis, with conduits anastomosed to the aorta proximally and to the coronary artery beyond the blockage. Graft choice strongly influences durability. The left internal mammary artery (LIMA) is the usual conduit to the left anterior descending artery, and it is often the conduit of choice in CABG surgery, specifically when grafted to the left anterior descending artery due to superior long-term patency rates. It has the highest patency rates of above 90% even at 10 years. The saphenous vein, harvested from the leg, remains the most common supplementary conduit, valued because it is long, relatively easy to access, and can be divided into segments for multiple bypasses. Its weakness is durability. In one angiographic series, vein graft patency fell from about 88% early after surgery to 50% at ≥15 years. Radial artery and right internal mammary artery grafts are increasingly used as additional arterial conduits, although several recent studies report suboptimal rates of right internal mammary artery graft failure.

CABG is generally preferred when anatomy is complex. Coronary artery bypass grafting is and continues to be the preferred revascularization strategy in patients with multivessel disease. It is also the traditional standard for left main disease, where randomized trials such as EXCEL have found PCI to be non-inferior only in selected patients with less complex anatomy.

Indications in stable disease

In chronic coronary syndromes, revascularization is usually considered for patients whose angina persists despite medical therapy, and for anatomy associated with high-risk prognosis, such as left main or proximal disease with reduced ventricular function. Trial evidence has tempered expectations of survival benefit. In the COURAGE trial (2007), adding PCI to optimal medical therapy did not reduce death or myocardial infarction compared with medical therapy alone. In the ISCHEMIA trial (2020), an invasive strategy with revascularization did not lower the rate of death, myocardial infarction, or hospitalization over a median of about 3.2 years, although it relieved angina more quickly in the early period. The consensus that follows is that in many stable patients revascularization mainly improves symptoms and quality of life rather than prolonging life.

Functional testing is used to select patients in whom revascularization is likely to help. Stress imaging documents inducible ischemia before a procedure is planned. In the FAME trial (2009), fractional flow reserve (FFR)-guided stenting reduced death, myocardial infarction, and repeat revascularization at one year compared with angiography-guided selection, while using fewer stents. The FAME 2 trial (2014) extended this, showing that patients with an FFR of 0.80 or lower benefited from PCI added to medical therapy, whereas patients with higher values did well with medication alone.

Heart team decisions

Choosing between PCI and CABG is made by a heart team that typically includes an interventional cardiologist and a cardiac surgeon. The SYNTAX score, an angiographic tool, grades lesion location, length, calcification, and bifurcation involvement; low, intermediate, and high scores are conventionally defined as 22 or less, 23 to 32, and 33 or more. In the SYNTAX trial (2009), patients with three-vessel or left main disease had more major adverse cardiac and cerebrovascular events after first-generation PCI than after CABG, and the gap widened as scores rose. The FREEDOM trial (2012) found lower rates of death, myocardial infarction, and stroke with CABG than with DES-based PCI in multivessel diabetic patients. Reduced left ventricular function, surgical risk, frailty, and comorbidity are weighed alongside anatomy. Guideline bodies in Europe and North America apply these scores with different emphasis, a point discussed further in the controversies section.

Emergency management of acute coronary syndromes

Primary PCI for STEMI and time targets

In ST-elevation myocardial infarction, the reperfusion strategy of first choice is primary PCI (PPCI), which is given to patients presenting within 12 hours of symptom onset. The current American guideline asks for a 12-lead electrocardiogram to be obtained and interpreted within 10 minutes of first medical contact (FMC) for everyone with suspected ACS, and for a STEMI-positive tracing, reperfusion proceeds without waiting for troponin results Obtain and interpret a 12-lead ECG within 10 minutes of FMC for all patients with suspected ACS. The system goal is a first-contact-to-device interval of 90 minutes or less at a PCI-capable hospital, extended to 120 minutes when the patient must be transferred from a hospital without catheterization facilities PPCI should be performed with a goal of FMC to device activation of ≤90 minutes, or ≤120 minutes in patients requiring hospital transfer. The older door-to-balloon benchmark of 90 minutes and door-to-needle benchmark of 30 minutes for fibrinolysis remain widely quoted in emergency system design The goal for patients with STEMI should be to achieve a door-to-needle time within 30 minutes and a door-to-balloon time within 90 minutes.

These targets drive the structure of regional STEMI networks: prehospital ECG transmission, early notification of the receiving catheterization team, and direct transport of patients past closer hospitals that lack PCI. Direct transfer to a PCI-capable facility has been associated with shorter reperfusion times and lower mortality compared with transport to the closest non–PCI-capable hospital. The time limit is grounded in trial and registry data showing that delay erodes the advantage of PCI. A pooled analysis of the National Registry of Myocardial Infarction found that when transfer-related delays exceeded 120 minutes from first contact, the survival advantage of primary PCI over fibrinolysis was negated when delays related to transfer for primary PCI exceeded 120 minutes from FMC, the survival advantage of primary PCI over fibrinolysis was negated.

Fibrinolytic therapy

Fibrinolysis (thrombolysis) is the alternative when the catheterization laboratory cannot be reached quickly. It is given when symptoms began within 12 hours and the expected delay to PCI exceeds 120 minutes, provided there is no contraindication In patients with STEMI and symptom onset of <12 hours and anticipated delay to PPCI >120 minutes from FMC, fibrinolytic therapy should be administered in patients without contraindication to reduce MACE. Fibrinolysis is not indicated when the ECG shows only ST-segment depression, unless a true posterior infarction is suspected Fibrinolytic therapy should not be administered when only ST-segment depression is present, unless true posterior STEMI is suspected.. Fibrin-specific agents are preferred, and tenecteplase has become the most used agent in many systems because it can be given as a single bolus Tenecteplase is the most widely used fibrinolytic in STEMI.. Prehospital administration is reasonable when transport times are long, commonly 60 to 90 minutes or more, and trained staff can record an ECG and transmit it for approval pre-hospital fibrinolysis is reasonable when it provides a substantial time saving, particularly with prolonged transport times of 60–90 minutes or more.

Fibrinolysis is always followed by a planned strategy for angiography. Patients who respond successfully are transferred for angiography and possible PCI within 2 to 24 hours, which is known as a pharmaco-invasive strategy If fibrinolysis is successful a pharmaco-invasive strategy (defined as angiography within 2 to 24 hours after fibrinolysis) is preferred.. When reperfusion appears to have failed, immediate rescue angiography is recommended The ACC/AHA recommend immediate angiography with rescue PCI for suspected failed reperfusion after fibrinolysis. Real-world data suggest that outcomes are worst where neither PCI nor transfer follows fibrinolysis, underscoring the need for timely transfer Fibrinolytic therapy in STEMI is infrequent, with high in-hospital mortality, especially in patients not undergoing PCI or transfer.

NSTEMI and unstable angina

Unstable angina and NSTEMI share the same ischemic symptoms and are separated mainly by the presence of myocardial necrosis measured with troponin, which is a biomarker of myocardial injury. Serial high-sensitivity measurements are used, with repeat sampling at 1–2 hours for high-sensitivity assays or 3–6 hours for conventional assays if cTn is non-diagnostic, repeat after 3–6 hours for conventional assays, or 1–2 hours for high-sensitivity assays. The timing of angiography depends on risk. Patients with haemodynamic instability, refractory ischemic pain, recurrent dynamic ST changes, or life-threatening arrhythmias are classed as very high risk and are generally referred for angiography within two hours Patients with a very high-risk profile – such as those with haemodynamic instability or cardiogenic shock, recurrent dynamic ECG changes (particularly intermittent ST-segment elevation), ongoing chest pain refractory to medical treatment, or life-threatening arrhythmias – warrant an immediate invasive strategy within two hours of admission. For the broader high-risk group, European guidance recommends an invasive approach within 24 hours, while the American guideline treats this as a reasonable option It recommends angiography during hospitalisation for intermediate- or high-risk patients, with an early invasive strategy within 24 hours being a reasonable option in high-risk cases. The evidence base for the 24-hour threshold is partly indirect, since guideline recommendations for an early IS in high-risk NSTE-ACS are predominantly based on a priori subgroup analyses of GRACE score ≥140 patients from the TIMACS and VERDICT trials. A randomized comparison of very early angiography (median 1.5 hours) with standard care (median 44 hours) in higher-risk patients did not show a difference in 12-month outcomes, although that trial was stopped early and was underpowered At 12 months, there was no significant difference in the primary outcome between the early IS (5.9%) and standard IS (6.7%) groups.

Antithrombotic therapy follows a similar logic. Patients receive aspirin together with a P2Y12 inhibitor, and the guideline favours prasugrel or ticagrelor over clopidogrel Prasugrel/ticagrelor preference over clopidogrel. Anticoagulation depends on the expected timing of angiography. Enoxaparin may replace unfractionated heparin when angiography is planned within 24 hours, and fondaparinux is preferred when it is not, while bivalirudin is an option during PCI consider enoxaparin as an alternative to UFH when invasive angiography is expected within 24 hours; use fondaparinux when invasive angiography is not expected within 24 hours. Radial access is the usual route for PCI in ACS, and the guideline notes that Radial-first approach (95% of PCIs in ACS cases).

Cardiogenic shock and in-hospital care

Cardiogenic shock or persistent haemodynamic instability is an indication for urgent revascularization regardless of how long symptoms have lasted Cardiogenic shock or haemodynamic instability warrants revascularization irrespective of the delay from symptom onset.. Infarct-related artery PCI is preferred, with surgical revascularization used when PCI is not feasible or fails PCI of the infarct-related artery is preferred; CABG is considered when PCI is not feasible or is unsuccessful.. Mechanical circulatory support, such as a microaxial flow pump, may be used in selected patients Microaxial flow pump in selected cardiogenic shock patients.. Early recognition is a priority because shock is a major determinant of short-term mortality.

After the acute phase, patients are monitored on telemetry because ventricular arrhythmias and bradyarrhythmias are most likely in the first hours and days, and rapid defibrillation and pacing capability are kept available. Serial ECGs and clinical reassessment continue to detect recurrent ischemia or heart failure. Anaemia is treated actively, and the American guideline recommends transfusion to maintain haemoglobin at or above 10 g/dL in ACS Red blood cell transfusion to maintain hemoglobin ≥10 g/dL.. Early mobilization is usually staged, beginning with sitting and standing and progressing to walking as haemodynamic status and rhythm allow, which reduces deconditioning and the risk of venous thromboembolism.

Complications and prognosis

Ischemic cardiomyopathy and heart failure

Ischemic cardiomyopathy refers to systolic left ventricular dysfunction in the setting of obstructive coronary artery disease and represents the most common cause of heart failure worldwide. After an infarct, the remaining ventricle often remodels adversely, with both end-diastolic and end-systolic volumes rising while the heart failure pattern of reduced ejection fraction develops. Patients with adverse remodeling have a higher rate of composite events, including cardiovascular death, recurrent infarction, heart failure, stroke, and resuscitated cardiac arrest, than patients without it .

The left ventricular ejection fraction (LVEF) is the main summary measure used to estimate prognosis and to guide device and drug decisions. Most patients have improved LVEF after an acute infarction, and in most of them the improvement can be confirmed after one month. In a registry of first infarctions treated with primary coronary intervention, LVEF was below 40% at discharge in about one in five patients . Recovery of LVEF is associated with a lower risk of cardiac arrest, death, and heart failure rehospitalization , and the extent of revascularization has been linked to LVEF improvement . Exercise capacity also carries prognostic information beyond LVEF: in one cohort with an LVEF under 35%, the least fit patients had a markedly higher relative risk of death than the fittest .

Arrhythmias and sudden cardiac death

Ventricular tachyarrhythmia is the largest single cause of death in the first two years after infarction, and the risk is concentrated in the first 30 days . Arrhythmias in the first 48 hours mainly reflect acute ischemia, electrolyte disturbance, and autonomic imbalance, whereas later arrhythmias arise from scar that provides a substrate for re-entry . Both re-entry and abnormal automaticity contribute, and a shift toward sympathetic dominance favors malignant rhythms .

Risk is not confined to patients with severely depressed function. Although those at risk often have an LVEF below 35%, . Factors predicting late arrhythmias include scar size, aneurysm, multivessel disease, and anterior infarct location . Early ventricular arrhythmias have been associated with age over 60, hypertension, diabetes, anterior infarction, higher Killip class, and delayed hospital arrival . Because no single test identifies high-risk patients reliably, guidance favors combining imaging, electrophysiological, and clinical information . Implantable defibrillators reduce arrhythmic death in appropriately selected patients, but the procedure is costly and carries risks, which is why risk stratification remains an active area .

Mechanical complications

The main mechanical complications are papillary muscle rupture, ventricular septal rupture, free-wall rupture, and pseudoaneurysm . They are most likely in large infarcts or in infarcts that were not reperfused . Reperfusion has sharply reduced their frequency: in recent STEMI series, septal rupture occurred in about 0.21%, papillary muscle rupture in 0.05%, and free-wall rupture in 0.01% of cases . Septal rupture is more common with older age, female sex, delayed reperfusion, and absent collateral circulation , and it typically appears around days three to five, with presentations ranging from a murmur to circulatory collapse .

The clinical course differs by lesion. Free-wall rupture usually causes rapid death, while papillary muscle rupture produces sudden mitral regurgitation . Free-wall rupture is often recognized only after out-of-hospital sudden death, so its true incidence is uncertain . Papillary muscle rupture is rarer in the anterolateral muscle, which receives a dual blood supply from the LAD and the circumflex . Unexplained cardiogenic shock in the days after infarction should prompt a search for a mechanical complication, with echocardiography as the key test . Definitive treatment is surgical or percutaneous repair, chosen according to symptoms .

Determinants of long-term prognosis

Long-term outcome depends on how much myocardium was lost and how much remains at risk. . Infarct size and scar burden shape remodeling and the chance that LVEF recovers . Renal function is a further determinant: chronic kidney disease contributes to arrhythmogenesis during acute infarction, alongside diabetes, hypertension, and dyslipidemia .

Secondary prevention and cardiac rehabilitation

Cardiac rehabilitation is a physician-directed, multidisciplinary programme that runs alongside drug therapy and revascularization. Its aims extend beyond fitness. Programmes are meant to soften the physical and psychological effects of heart disease, lower the chance of sudden death or a repeat heart attack, control symptoms, and influence the underlying arterial disease itself This multifactorial process is designed to limit the adverse physiologic and psychological effects of cardiac illness, reduce the risk of sudden death or reinfarction, control cardiac symptoms, stabilize or reverse the atherosclerotic process. A typical outpatient programme pairs baseline assessment with nutritional counseling, weight management and body composition, cardiovascular and risk factor management, psychosocial management, aerobic exercise training, strength training, physical activity counseling, and program quality. Supervised training forms the physical core. It facilitates an enhancement of cardiovascular fitness, a reduction in heart rate, blood pressure and cardiac remodeling, an increase in the left ventricular ejection fraction, the optimization of endothelial function, and a reduction in inflammation and oxidative stress. Psychological care is folded in as well. When staff detect distress, they can direct the patient to a psychologist or counselor Addressing psychosocial well-being, including assessing participants' psychosocial needs and providing referrals to therapists or counselors when appropriate, is an important component of cardiac rehab programs.

Evidence for benefit is strongest for some outcomes and weaker for others. An earlier meta-analysis estimated that CR leads to a 27% reduction in all-cause mortality and 31% for cardiac deaths. Whether all-cause mortality falls in contemporary practice remains uncertain, which is why an individual-patient-data meta-analysis of trials from 2010 to 2020 was planned Despite meta-analyses of randomised trials demonstrating a positive impact of CR on cardiovascular mortality, hospitalisation, exercise capacity and health related quality of life, the impact of CR on all-cause mortality remains uncertain, especially in the context of contemporary clinical practice. Quality-of-life gains are more consistent. In one pooled analysis the physical HRQOL effect was clearer, while the emotional effect's confidence interval crossed zero. Dose also appears relevant. A meta-regression suggested that patients with CVD should be prescribed at least 36 sessions to reduce PCI. Results also suggested that patients should be prescribed at least 12 sessions to reduce all-cause mortality, although this recommendation warrants replication of our results.

Participation is the main weakness. The global enrollment rate to CR programs is said to be low, standing at less than 30%, and variation in enrollment rates is well observed with regard to region and healthcare settings. Distance is a major deterrent: long wait times and travel distances over 24 km are associated with a 71% lower likelihood of participation. Cost matters too. One estimate put a full 36-session programme at $1900–$2500 out-of-pocket. Women are less likely to be referred, and a metanalysis showed that while referral to CR was less than 50%, women were less likely to be referred for CR (39.6%, OR 0.68, 95% CI 0.62-0.74). Among referred women who did not enroll, the commonest obstacles were not knowing about CR, not being contacted by the program, cost, and finding exercise tiring or painful. Some authors argue that these gaps reflect structural problems rather than a lack of motivation The problem is structural, not motivational. Proposed remedies include automatic referral and assisted enrollment to improve CR participation. A small number of studies suggest that incentive-based strategies, as well as home-based programs, may contribute to improving CR attendance and completion rates. Language is another factor. A US Million Hearts infographic notes that one of the best predictors of cardiac rehab referral is whether the eligible person speaks English.

Rehabilitation also serves as a platform for lifestyle change, though the specific recommendations below are general clinical guidance rather than findings from the sources cited above. Dietary advice usually favors Mediterranean- or DASH-style patterns, with more vegetables, fruit, whole grains, legumes, fish, and unsaturated fats, and less processed meat, sugary drinks, and refined carbohydrate. Higher fiber intake and lower sodium intake are part of this approach, since they bear on hypertension and cholesterol. Smoking cessation is a central target, supported by counseling and pharmacotherapy. Weight reduction, even if modest, can improve blood pressure, glucose, and lipids in people with obesity or diabetes. Physical activity targets commonly cite at least 150 minutes per week of moderate aerobic activity, or 75 minutes of vigorous activity, plus muscle-strengthening work on two or more days.

Adherence is treated as a clinical problem in its own right. Programmes teach patients how to take their medicines and try to identify what gets in the way of following through, but adherence depends on what happens after discharge. Antiplatelet agents, statins, and blood-pressure drugs are often stopped early, sometimes because of side effects or cost. Regular follow-up lets clinicians recheck cholesterol, blood pressure, and glucose, adjust doses, and revisit goals. Support can come from pharmacist-led counseling, reminders, simpler once-daily regimens, and continuity with a primary care team.

Epidemiology and global burden

Ischemic heart disease (IHD) is the term the Global Burden of Disease (GBD) project uses for coronary artery disease and its clinical consequences. GBD defines IHD as acute myocardial infarction, chronic stable angina, chronic IHD, and heart failure due to IHD. For 2021, the study estimated 254.3 million prevalent cases, 9.0 million deaths and 188.4 million DALYs. The deaths were equivalent to 13.2% of total global deaths, and the DALYs made up 6.5% of global DALYs. These are modelled rather than directly counted figures. GBD results combine data and estimates, so 95% uncertainty intervals are reported for each count and rate. Coverage is weakest where registries are thin, and misclassification and limited resources in low-SDI areas make accurate assessment harder.

Where CAD ranks depends on the metric. Over the past three decades, IHD has remained the most common cause of global deaths by age-standardized death rate, and the second most common cause of DALYs for all ages and sexes combined. A later GBD release, however, reported that IHD had the highest global age-standardized DALY rate of all diseases. Deaths weight premature mortality heavily, whereas DALYs add years lived with disability. Planners therefore read the two sets of rankings differently when deciding how to allocate resources across noncommunicable diseases.

Trends differ sharply between countries. Over 1990–2021, the age-standardized mortality rate for IHD fell by 31.57%, yet the absolute number of deaths rose, reaching 167.5% of the 1990 figure. In high-income countries, the decline began earlier. In most European countries a 30% decline in CHD deaths was registered from 1980 to 2010, and similar reductions were observed in the US, Canada, and Australia, where rates are now less than half of 1980s levels. Part of that fall came from fewer new events rather than from treatment. An earlier study across 21 countries showed that approximately three quarters of the fall in coronary heart disease mortality was due to a decline in event rates. Risk-factor change, especially in the Nordic countries, is cited as the main driver, while treatment contributed less. Since about 2000, some high-income countries have shown a plateau, which has been linked to rising diabetes and obesity.

Low- and middle-income countries (LMICs) show a different pattern. Although morbidity and mortality from acute coronary syndrome are declining in most high-income countries, they are rising at an alarming pace in LMICs. Increasing trends have been observed in Eastern Europe, and in Asian and Latin American countries. Within the same region the picture can vary. A time-trend study in Latin America found that coronary mortality was falling in Argentina, modestly falling in Colombia, and substantially increasing in Mexico. Deaths in LMICs occur at younger ages than in high-income countries, and more than 80% of CVD deaths occur in LMICs. The World Heart Federation attributes the rise partly to rapid urbanization and the marketing of tobacco, processed foods, and sugary drinks, which increase lifestyle-related risk.

Population aging and urbanization explain much of the rising absolute case count even where age-specific rates are falling. GBD decomposition analyses separate the change in burden into the effects of population growth, population aging, changes in exposures to each risk factor, and changes in risk-deleted rates. Better survival after acute events also adds to prevalence. Increased survival from cardiovascular comorbidities such as hypertension and coronary artery disease means more people live with the chronic disease. Most IHD patients in the GBD 2021 estimates are over 60, and males outnumber females.

Burden metrics serve different purposes in planning. Prevalence indicates how many people need ongoing care and secondary prevention. Incidence and mortality track new events and the effectiveness of acute care. DALYs combine years of life lost to premature death with years lived with disability, which makes them useful for comparing IHD with other conditions and for setting priorities in public health budgets. Because the sum of DALYs can mask differences in age structure, age-standardized rates are reported alongside absolute counts. The GBD also reports results stratified by the Socio-demographic Index, which allows burden to be compared across development levels and with social determinants of health.

Sex, age, and social disparities

Sex differences in presentation, diagnosis, and treatment

Clinical coronary disease tends to appear about a decade later in women than in men. Cardiovascular disease develops 7 to 10 years later in women than in men, and the risk in women is often underestimated because of a misperception that females are protected. Before menopause, the loss of estrogen's protective effects is usually cited as the biological explanation for the later onset, which is why menopause is often treated as a turning point in female risk. The persistence of the belief has practical consequences, because it shapes how clinicians triage women with chest discomfort.

Symptoms are one of the main sources of delay. Women are more likely to report fatigue, breathlessness, nausea, or upper-abdominal discomfort rather than the retrosternal pressure that clinicians are trained to expect, and such complaints can be dismissed or attributed to non-cardiac causes. Atypical symptom presentations and a higher prevalence of non-obstructive disease, including MINOCA and SCAD, contribute to underdiagnosis. Under comparable clinical findings, fewer women than men undergo diagnostic imaging, percutaneous coronary intervention, and statin therapy. Among women with ST-elevation myocardial infarction, higher rates of bleeding complications and 30-day mortality have been reported, which points to a need for treatment protocols adjusted for sex rather than simply extrapolated from male-dominated data.

Evidence gaps reinforce these differences. Enrolment of women in trials has lagged behind their share of the disease. In a colchicine trial in chronic coronary disease, women made up only about 15% of participants. Measured against disease prevalence, the participation to prevalence ratio for females is lower in trials for heart failure and coronary artery disease compared with hypertension. Because most guideline recommendations derive from these trials, drug doses, risk thresholds, and revascularization criteria are often applied to women with limited sex-specific data. Access to secondary prevention is similarly uneven: cardiac rehabilitation participation is significantly lower among women, partly because of referral bias and programs not designed around women's needs.

Age and multimorbidity

The probability of coronary disease rises steeply with age, and most deaths and hospitalizations from CAD occur in people over 65. Older patients differ from younger ones in several ways that affect both presentation and management. Symptoms are often atypical, and an acute infarction may be recognized late, when it presents as confusion, falls, or worsening breathlessness rather than classic chest pain. Comorbidities such as chronic kidney disease, diabetes, heart failure, atrial fibrillation, and cognitive impairment are common, and each interacts with treatment choices. Older adults are also more vulnerable to the bleeding risk of combined antiplatelet and anticoagulant therapy and to the adverse effects of polypharmacy.

Decisions about revascularization and intensive drug therapy must therefore weigh frailty, life expectancy, and functional independence alongside the anatomy of the disease. Older adults have historically been under-represented in randomized trials, so the evidence base for their care is thinner, and clinicians frequently extrapolate from younger trial populations. Cardiac rehabilitation and follow-up visits also become harder to sustain when mobility, transport, and caregiving are limiting factors.

Socioeconomic position and neighborhood environment

Socioeconomic position is one of the most consistent correlates of CAD burden. Four measures have been consistently associated with cardiovascular disease in high-income countries: income level, educational attainment, employment status, and neighborhood socioeconomic factors. Individual-level disadvantage carries prognostic weight in established disease: in one review, patients with lower family income, limited education, or lower-prestige jobs were 1.5–2.0 times more likely to die in the years following diagnosis of angina pectoris and myocardial infarction.

Neighborhood context adds an effect beyond personal circumstances. In a surveillance study of four US communities, inverse associations of neighborhood socioeconomic status with out-of-hospital fatal coronary heart disease were seen in all race-gender groups, and the magnitude of these associations was larger among women than men. A Canadian cohort of more than 51,000 patients admitted with myocardial infarction found that each $10,000 decrease in median neighborhood income was associated with a 10% increase in all-cause mortality over one year, with the figure given in Canadian dollars. Proposed mechanisms include chronic stress tied to local social conditions, limited access to affordable healthy food, and greater exposure to air pollution, which has been linked to endothelial dysfunction and atherosclerosis. These mechanisms are central to the concept of social determinants of health, which treats where people live, work, and learn as causal pathways to disease rather than as background variables.

The pattern of risk also differs by setting. In Bangladesh, for example, higher-socioeconomic-status people tend to be physically inactive and have higher percentages of hypertension, diabetes, and overweight, while tobacco use is more prevalent among lower-status people. Such findings indicate that the same disease can reflect different risk profiles across social strata, so that prevention strategies need to be tailored rather than uniform. Approximately 80% of the global burden of cardiovascular disease is accumulated in low- and middle-income countries, which underlines the international dimension of these gradients.

Health-system access, insurance, and language

Even after clinical need is accounted for, access to care shapes disparities in treatment and outcomes. In one study of patients hospitalized for cardiovascular disease, the most deprived neighborhoods were also the ones whose residents were more likely to be uninsured, and these patients had more comorbidities such as diabetes, hypertension, and renal disease at admission. Lack of insurance can delay outpatient visits, restrict access to cardiac rehabilitation, and make long-term drug therapy such as lipid-lowering agents or antiplatelet agents financially difficult to sustain, which in turn affects adherence and quality of life after an event.

Language barriers operate through similar pathways. Patients with limited proficiency in the dominant language may have difficulty describing symptoms accurately, understanding discharge instructions, or following complex medication regimens, and they may not have access to professional interpreters at every step. Low health literacy compounds these problems. Health-system measures that address them, such as interpreter services, multilingual educational materials, and outreach through primary care, are therefore part of efforts to reduce the unequal burden of CAD across groups.

Public health and prevention policy

Population-level strategies

Population-wide measures aim to shift risk across a whole society, not only in people already identified as high risk. Tobacco control has the most extensive evidence. An estimated 1.9 million avoidable CHD deaths a year, about a fifth of the global total, are linked to smoking and second-hand exposure About 1.9 million avoidable deaths from coronary heart disease (CHD) per year (approximately 21% of all CHD deaths globally) are attributable to tobacco use and exposure to second-hand smoke. Price measures such as excise taxes reduce consumption, with downstream benefits for the heart Increases in tobacco taxation, for example, have been directly linked with a reduction in tobacco consumption, thereby leading to better heart health. A 2014 US Surgeon General's report judged the evidence sufficient to infer a causal link between smoke-free policies and fewer coronary events among people under 65 there is sufficient evidence to derive a causal relationship between a smoke free policy and a reduction in coronary events in a population younger than 65 years of age. In the CARDIA cohort, residents of areas with smoke-free rules had lower rates of incident cardiovascular disease, but the estimates did not reach statistical significance participants living in an area with a restaurant, bar, or workplace smoke-free policy had lower risk of incident cardiovascular disease compared to those in areas without smoke-free policies.

Salt policy rests on a different evidence base. A 2.5 g daily cut in intake has been paired with roughly 20% fewer cardiovascular events in pooled long-term follow-up of earlier trials a 2.5 g/day reduction being associated with a 20% reduction in CVD events. A 2010 simulation in the New England Journal of Medicine estimated that a 3 g daily reduction would affect CHD events about as much as halving tobacco use a reduction in dietary salt of 3 g per day would have approximately the same effect on rates of CHD events as a 50% reduction in tobacco use. Direct trial evidence is less certain. An updated Cochrane review, first published in 2011, found that event data rested heavily on a single trial in retirement homes, and it judged the overall findings inconclusive There was weak evidence of benefit for cardiovascular events, but these findings were inconclusive and were driven by a single trial among retirement home residents. Its authors nonetheless argued that advice to reduce salt should continue, with reductions in hidden salt in processed foods as a complementary measure. Observational work has produced a J-shaped curve linking very low intake to excess risk, but critics point to reverse causality and imprecise spot-urine measurement several studies, including cohort studies, have suggested a J-shaped relationship between salt intake and CVD risk. However, these studies had severe methodological problems, such as reverse causality and measurement error due to assessment of salt intake by spot urine. Global guidance sets the target below 5 g a day, against an average intake near 10 g The WHO has set a global target of reducing the population salt intake from the current level of approximately 10 g daily to <5 g daily.

National blood pressure and cholesterol programs

National programs have been the main vehicle for turning these measures into practice. The Canadian Hypertension Education Program, which issued updated recommendations every year, was associated with a rise in the share of treated patients with controlled blood pressure, reaching 65.7% by 2006 A repeat survey in 2006 showed that the percentage of treated hypertensive patients with the blood pressure controlled had risen to 65.7%.. Over its first decade, antihypertensive prescriptions rose by 84%, with faster declines in mortality from stroke, heart failure and myocardial infarction the number of prescriptions for antihypertensive medications had increased by 84.4% associated with a significant greater decline in the yearly mortality from stroke, heart failure and myocardial infarction. These are before-and-after comparisons, so they show association rather than proof of causation. A community program in two rural Kentucky counties recorded better hypertension control and substantial reductions in cardiovascular deaths in the intervention counties In the intervention counties, systolic and diastolic blood pressures of both men and women decreased despite the five-year increase in age; moreover, hypertension was better controlled after the program, and substantial decreases in deaths due to cardiovascular disease were seen. In the United States, the National Cholesterol Education Program, established in 1985, played a comparable role for lipids by issuing successive expert panel reports on LDL targets and treatment thresholds.

Modelling has been used to justify national investment. An Israeli analysis projected about 2,242 lives and 24,433 DALYs saved over 20 years around 2,242 lives, 35,117 years of life or 24,433 disability adjusted life years will be saved due to decreased mortality at a cost of $352.7 million. Global targets reflect the same logic. The World Health Assembly endorsed a 25% relative reduction in raised blood pressure by 2025 in 2013 a 25% relative reduction of raised BP. Observational results are not uniformly consistent, however. In an analysis of ALLHAT participants, sustained systolic control was not associated with coronary outcomes there was no association between sustained SBP control and CHD/nonfatal MI and mortality, and in US veterans the lowest mortality occurred at systolic pressures of 130 to 139 mm Hg the lowest mortality risk was observed in those with systolic BP of 130 to 139 mm Hg.

Primary care is where these programs operate day to day. Clinicians measure blood pressure, estimate risk with validated equations, and decide which patients need antihypertensive or lipid-lowering treatment. Population gains therefore depend on the reach of primary health care as much as on any single drug or policy.

Guidelines and the revision of recommendations

Guidelines translate trial and cohort results into recommendations for clinicians and health systems. They are revised as new randomized trials report and as older conclusions are re-examined, which is why the same question can be answered differently over time. The salt example shows the tension. Global agencies adopted a firm numerical target while some reviewers judged the direct outcome evidence weak, and advocates argue that a national strategy to reach 5 g a day would bring major health gains and cost savings Every country should implement a strategy to reduce daily salt intake to the WHO target of 5 g; this action will result in major public health improvements and cost savings.

Screening, cost and overdiagnosis

Preventive programs face a trade-off between benefit, cost, and harm. Screening for risk factors or subclinical disease labels people who may never experience an event, and treatment that follows carries side effects and expense. The absolute benefit for any individual depends on baseline risk, so the same test can be cost-effective in one population and wasteful in another. Policy choices therefore weigh the number of people treated against the events prevented, and they must account for diagnostic accuracy, follow-up testing, and the burden of evidence-based adherence in real practice.

History of understanding

Clinical descriptions of the coronary syndrome predate any understanding of infarction. William Heberden defined the clinical profile of angina pectoris in 1772, and Edward Jenner's observations about intracoronary thrombosis in patients who had died with such symptoms came about a century later. In 1842, Marshall Hall attributed sudden death in these patients to interruption of the coronary circulation. The first complete description of coronary thrombosis as a clinical entity followed in 1910, when Obrastzow and Straschecko published it.

The decisive account came from James Herrick of Chicago. In his 1912 paper, he described the relationship between myocardial infarction and coronary thrombosis, and he argued that thrombosis in the coronary artery leads to the symptoms and abnormalities of heart attacks and that this was not inevitably fatal. The paper was largely ignored. Herrick later recalled that there was no repercussion for six years. He had supported his claims with experiments in which he reviewed pathologic findings and began experiments on laboratory animals, ligating coronary arteries to evaluate their effects, and by 1918 he was one of the first to encourage electrocardiography in the diagnosis of myocardial infarction.

Pathological work tied these threads together. Understanding of the underlying atherosclerosis and arterial plaque formation connected the chain of causation for heart attack to stenotic or ulcerative and thrombotic obstruction of coronary vessels. For roughly fifty years after Herrick, however, the prevailing concept of the pathogenesis of acute MI revolved around gradual occlusion of a coronary artery by an atherosclerotic process with secondary thrombotic occlusion. Thrombosis as a primary trigger was not widely accepted until the modern era, and large randomized trials confirming the efficacy of thrombolytic therapy were not performed until over 70 years after Herrick's report. Direct visual proof came in 1980, when coronary angiography confirmed the thrombotic occlusion.

Coronary angiography was itself accidental. On 30 October 1958 at the Cleveland Clinic, F. Mason Sones, while imaging the aorta, noted that the catheter had inadvertently entered the right coronary artery, and then set out to deliberately image the coronary vessels. He refined and standardized selective coronary angiography, using smaller amounts of dye and improved X-ray imaging, and his protocols remain the basis of practice. The method also supplied the anatomical map that surgery needed. The coronary angiogram provided the stimulus for the development of aortocoronary bypass surgery.

Bypass surgery developed in parallel. Earlier direct approaches, such as Åke Senning's 1961 use of a pericardial patch to enlarge a diseased left main coronary artery, showed that the coronary lumen could be reconstructed, but outcomes were poor for left main repairs. René Favaloro performed his first coronary bypass operation in May 1967 with an interposed saphenous vein graft, and the procedure's ability to relieve angina pectoris and, in some cases, improve survival established mechanical revascularization as a treatment. Some historians credit an earlier operation in New York in 1960, a claim that is not universally accepted.

The next shift was catheter-based. Andreas Grüntzig performed the first percutaneous transluminal coronary angioplasty at the University Hospital in Zurich on 16 September 1977. His method drew on the Dotter technique used in peripheral arteries, but he sought a smaller device that could be inflated. The balloon widened the narrowed segment, which was a different approach from surgical bypass. Its main limitations were the considerable rates of restenosis and abrupt closure. Coronary stents were developed to address these problems. Jacques Puel implanted the first coronary stent, a Wallstent, in 1986, and regulatory approval of the first scientifically evidence-based stent, the Palmaz-Schatz, followed in 1994. Later, drug-eluting designs were introduced as a further step.

Pharmacological treatment changed the goal from relieving symptoms and restoring flow to slowing the underlying disease. Statins emerged from a 1973 discovery of compactin (mevastatin) by Akira Endo in Japan. Lovastatin was approved in the United States in 1987, and the 1994 Scandinavian Simvastatin Survival Study (4S) showed reduced mortality in patients with established disease. These drugs gave the field a way to address atherosclerosis itself, alongside revascularization.

Over time, the classification has broadened. The early model centered on two clinical events, angina and infarction, and on obstructive lesions visible on angiography. Later work recognized that patients with symptoms or even infarction may have no obstructive stenosis. Microvascular dysfunction and coronary vasospasm came to be recognized as causes of ischemia, and diagnosis increasingly relies on invasive physiological measurements rather than the anatomy alone.

Controversies and unresolved questions

Revascularization strategy in stable multivessel disease

Guidelines on stable multivessel disease have diverged. The 2021 ACC/AHA revascularization guideline moved CABG for three-vessel disease with preserved left ventricular function and no left main disease down to class 2b, a decision that reflects new evidence showing no advantage of CABG over medical therapy alone to improve survival. The 2023 ACC/AHA chronic coronary disease guideline instead rated revascularization for multivessel disease suitable for either CABG or PCI as reasonable to lower the risk of events, a class 2a recommendation.

Surgical societies objected. An STS/AATS-endorsed rebuttal argued that the guideline lumped together CABG and PCI and compared them with medical therapy, using a meta-analysis that included few patients with significant three-vessel disease, and it pointed to consistent evidence that CABG improves survival over PCI in complex three-vessel disease. A multisociety endorsement of the 2024 ESC recommendations made a parallel argument, criticizing the ACC/AHA document for inappropriately extrapolating ISCHEMIA to compare CABG versus OMT, although ISCHEMIA was not a randomized comparison of those two strategies. The ESC guideline itself recommends revascularization for functionally significant 3-vessel disease in patients with left ventricular ejection fraction above 35%, as a class I recommendation. The disagreement is partly structural: there is not a single published study designed to directly address the CABG-versus-medical-therapy comparison, so guideline authors must infer from indirect evidence, including FREEDOM, in which all-cause mortality was higher in the PCI group than in the CABG group after 5 years, while cardiovascular mortality did not differ.

Routine coronary artery calcium screening

Whether coronary artery calcium scoring by CT should be used broadly remains contested. The USPSTF concluded that there is insufficient evidence to assess the benefits and risks of adding CAC screening to traditional risk assessment in asymptomatic adults. Professional guidelines are more permissive for intermediate-risk people, but they share a gap: all guidelines recognize the lack of evidence that management based on the CAC score leads to a reduction in cardiovascular disease. Age thresholds also differ, with the ACC/AHA and Canadian guidance using CAC scoring more sparingly for low-risk individuals under 45.

The central objection concerns low-risk populations, where most positive results are false positives. Earlier USPSTF reasoning held that harms from false-positive tests, such as unnecessary invasive procedures, overtreatment, and labeling, are likely to occur. Proponents counter that a zero score can be informative; for example, one guideline notes that in people aged 76 to 80 a CAC score may be reasonable to reclassify patients to a lower risk category and withhold statins in case of a zero score. Whether that reassurance is worth the cost and radiation of population-wide testing is unresolved.

Lipoprotein(a) and universal testing

The main unresolved question about lipoprotein(a) is whether lowering it reduces events. Pelacarsen, an antisense oligonucleotide, has lowered Lp(a) substantially in earlier studies; in phase 2 work, 80% reduction was seen with 20 mg weekly, compared with 6% in placebo. The phase 3 Lp(a)HORIZON trial is testing clinical outcomes in 8,323 patients with clinically established CVD and an elevated Lp(a) level of ≥70 mg/dL, with an expanded MACE primary endpoint over approximately 4 years. Until such trials report whether the reduction translates into fewer events, the benefit of treating elevated Lp(a) remains an assumption.

This matters for testing policy. Lp(a) levels are largely inherited, which supports measuring it once in adults as a risk marker, and some recent guidance documents recommend a single measurement for all adults. That recommendation assumes that identifying high levels will change treatment and improve outcomes, which the outcome trials have not yet confirmed. Critics argue that universal testing before then could generate labels without a proven intervention, while supporters argue that a lifetime measurement captures risk that standard lipid panels miss.

Inflammation-targeted therapy, antiplatelet duration, and microvascular disease in women

Anti-inflammatory treatment is one of the more promising yet unsettled areas. The CANTOS trial of canakinumab, an interleukin-1β antibody, reduced recurrent events without changing LDL cholesterol, but the reduction in events did not translate into lower all-cause mortality and fatal infections increased. Colchicine has produced more favorable event reductions in trials of recent myocardial infarction (COLCOT) and stable disease (LoDoCo2), yet open questions remain about which patients benefit, how gastrointestinal and infectious adverse effects weigh against benefit, and whether inflammatory markers such as C-reactive protein should guide therapy.

The optimal length of dual antiplatelet therapy after stenting is also debated. Extending P2Y12-inhibitor therapy beyond 12 months after drug-eluting stent placement reduces stent thrombosis, myocardial infarction, and stroke, but it increases bleeding, and the longer-duration arm showed an imbalance in mortality. Shorter regimens and monotherapy strategies have gained acceptance in selected patients, but the right duration depends on the balance between ischemic and bleeding risk, which varies between individuals.

Finally, the management of microvascular disease in women remains poorly defined. Many women with angina have no obstructive lesions on angiography and are diagnosed through physiological testing, but therapy is largely extrapolated from small studies. Hormonal changes around menopause and sex differences in cardiac imaging findings add complexity, and randomized evidence specific to women with non-obstructive disease is still limited, with the WARRIOR trial among the efforts intended to address that gap.

References

1. The coronary circulation in healthy and diseased states - PMCpmc.ncbi.nlm.nih.gov
2. Coronary Artery Anatomy and Coronary Perfusion Pressure - OpenAnesthesiaopenanesthesia.org
3. 4/22/11 STS Adult Cardiac Surgery Database Training Manual, v2.73sts.org
4. Influence of coronary territory on flow profiles of saphenous vein graftsncbi.nlm.nih.gov
5. Circumflex Artery: Function, Anatomy & Locationmy.clevelandclinic.org
6. Left Anterior Descending Coronary Artery - an overviewsciencedirect.com
7. human coronary collateral circulation: development and clinical importanceacademic.oup.com
8. The human coronary collateral circulation: development and clinical importance - PubMedpubmed.ncbi.nlm.nih.gov
9. Gradual occlusion of a coronary artery: An experimental study - ScienceDirectsciencedirect.com
10. The dynamics of the coronary collateral circulationnature.com
11. Salient features of the coronary collateral circulation and its clinical relevancesmw.ch
12. The Role of Lipids and Lipoproteins in Atherosclerosis - Endotext - NCBI Bookshelfncbi.nlm.nih.gov
13. A Two-Phase Model of Early Atherosclerotic Plaque Development with LDL Toxicity Effectsarxiv.org
14. Stent with anchors to prevent vulnerable plaque rupture during deploymentimage-ppubs.uspto.gov
15. Fibrous Plaque - an overviewsciencedirect.com
16. Pathophysiology of Coronary Artery Diseaseahajournals.org
17. Pathogenesis of Atherosclerosisjacc.org
18. Management and Outcome of Patients With Acute Coronary Syndrome Caused by Plaque Rupture Versus Plaque Erosion: An Intravascular Optical Coherence Tomography Studyahajournals.org
19. Uncovering Plaque Erosion: A Distinct Pathway in Acute Coronary Syndromes and a Gateway to Personalized Therapymdpi.com
20. Pathogenesis of plaque erosion - ScienceDirectsciencedirect.com
21. Plaque erosion and acute coronary syndromes: phenotype, molecular characteristics and future directionsnature.com
22. Markers associated with arteriovascular events and methods of use thereofimage-ppubs.uspto.gov
23. A Two-Phase Model of Early Fibrous Cap Formation in Atherosclerosisarxiv.org
24. Mechanisms of Oxidized LDL-Mediated Endothelial Dysfunction and Its Consequences for the Development of Atherosclerosisncbi.nlm.nih.gov
25. Pathophysiology of Acute Coronary Syndromes—Diagnostic and Treatment Considerations - PMCpmc.ncbi.nlm.nih.gov
26. Verona Coronary Physiology Interventional Registrycdn.clinicaltrials.gov
27. Plaque erosion: a new in vivo diagnosis and a potential major shift in the management of patients with acute coronary syndromes - PMCpmc.ncbi.nlm.nih.gov
28. New Insights Into Plaque Erosion as a Mechanism of ACS - Mass General Advances in Motionadvances.massgeneral.org
29. Cardiovascular Risk Factors. Insights From Framingham Heart Study - Revista Española de Cardiología (English Edition)revespcardiol.org
30. Framingham Heart Studyframinghamheartstudy.org
31. Description of the Framingham Heart Study data for Genetic Analysis Workshop 13ncbi.nlm.nih.gov
32. Framingham Heart Studybritannica.com
33. Framingham Heart Study: JACC Focus Seminar, 1/8 - ScienceDirectsciencedirect.com
34. Presumed Mechanisms Underlying Lipoprotein(a)-caused Atherosclerosis - PMCpmc.ncbi.nlm.nih.gov
35. Lipoprotein(a)'s Role in Atherosclerosis and Aortic Stenosis: A Contemporary Literature Reviewncbi.nlm.nih.gov
36. Full article: Lipoprotein(a) in atherosclerosis: from pathophysiology to clinical relevance and treatment optionstandfonline.com
37. Chronic kidney disease induces a distinct lipidomic signature and accelerates atherosclerosis progression in a novel minipig model - PMCpmc.ncbi.nlm.nih.gov
38. Framing Cause-Effect Relationship of Acute Coronary Syndrome in Patients with Chronic Kidney Diseasencbi.nlm.nih.gov
39. Carotid Atherosclerosis in Chronic Kidney Disease: Pathophysiological Mechanisms, Prevention and Tailored Clinical Management - PMCpmc.ncbi.nlm.nih.gov
40. Coronary Artery-Specific Changes in Patients with Chronic Kidney Disease - PMCpmc.ncbi.nlm.nih.gov
41. Mechanisms of Cardiovascular Disorders in Patients With Chronic Kidney Disease: A Process Related to Accelerated Senescencencbi.nlm.nih.gov
42. Enhanced tyrosine sulfation is associated with chronic kidney disease-related atherosclerosisncbi.nlm.nih.gov
43. Deeper insight into chronic kidney disease-related atherosclerosis: comparative proteomic studies of blood plasma using 2DE and mass spectrometryncbi.nlm.nih.gov
44. Full article: Diagnosing and treating stable angina: a contemporary approach for practicing physicianstandfonline.com
45. Coronary Artery Disease and Stable Anginaunboundmedicine.com
46. Stable Angina - StatPearls - NCBI Bookshelf - NIHncbi.nlm.nih.gov
47. Anginal Equivalent - an overviewsciencedirect.com
48. ACS in Special Populations: Women, Diabetic, and Elderly Patientsintechopen.com
49. Prevalence and determinants of silent myocardial ischemia in patients with type 2 diabetes in Cameroon: a cross-sectional studyncbi.nlm.nih.gov
50. Prevalence and Predictors of Silent Myocardial Ischemia in Asymptomatic Type 2 Diabetes Mellitus: A Cross-Sectional Study From North India - PubMedpubmed.ncbi.nlm.nih.gov
51. Prevalence and Predictors of Silent Myocardial Ischemia in Diabetic Patients - PMCpmc.ncbi.nlm.nih.gov
52. Prevalence and Predictors of Silent Myocardial Ischemia in Diabetic Patientsncbi.nlm.nih.gov
53. Silent Myocardial Ischemia in CKD Stage 3-5: Prevalence and Predictorsncbi.nlm.nih.gov
54. Chronic coronary syndrome: Overview of care - UpToDateuptodate.com
55. Chronic Stable Anginasciencedirect.com
56. Study on syndrome differentiation and treatment in the management of chronic stable coronary artery disease to improve quality of lifencbi.nlm.nih.gov
57. Coronary Heart Disease and Stable Anginaunboundmedicine.com
58. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelinesjacc.org
59. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines - ScienceDirectsciencedirect.com
60. Acute Coronary Syndromes: AHA/ACC 2025 Guideline Summaryreference.medscape.com
61. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelinesahajournals.org
62. Updated GRACE ACS Risk and Mortality Calculatormdcalc.scholasticahq.com
63. GRACE scores or high-sensitivity troponin for timing of coronary angiography in non-ST-elevation acute coronary syndromeslink.springer.com
64. ACC 2025: ACC/AHA Guideline on the Management of Acute Coronary Syndromesreference.medscape.com
65. What US Cardiology Can Learn From the 2023 ESC Guidelines for the Management of Acute Coronary Syndromesncbi.nlm.nih.gov
66. GRACE scores or high-sensitivity troponin for timing of coronary angiography in non-ST-elevation acute coronary syndromes - PMCpmc.ncbi.nlm.nih.gov
67. Importance of Risk Assessment in Timing of Invasive Coronary Evaluation and Treatment of Patients With Non–ST‐Segment–Elevation Acute Coronary Syndrome: Insights From the VERDICT Trialahajournals.org
68. INOCA: Ischemia in non-obstructive coronary arteries - ScienceDirectsciencedirect.com
69. Coronary Microvascular Spasm: Clinical Presentation and Diagnosis - International Heart Spasms Allianceinternationalheartspasmsalliance.org
70. INOCA: A Common, Dangerous, Often Overlooked Cause of Chest Painconsultqd.clevelandclinic.org
71. Unveiling the Microvasculature: The Index of Microcirculatory Resistance and Its Expanding Role in Cardiovascular Care - PMCpmc.ncbi.nlm.nih.gov
72. INOCA and MINOCA: coronary vasomotor disorders in clinical practicemedicinetoday.com.au
73. Coronary spasm and vasomotor dysfunction as a cause of MINOCAeurointervention.pcronline.com
74. Myocardial Infarction with Nonobstructive Coronary Arteries (MINOCA): Current Insights into Pathophysiology, Diagnosis, and Managementncbi.nlm.nih.gov
75. Coronary Arterial Function and Disease in Women With No Obstructive Coronary Arteriesahajournals.org
76. Ischemia with No Obstructive Arteries (INOCA): A Review of the Prevalence, Diagnosis and Management - ScienceDirectsciencedirect.com
77. Spontaneous, Postpartum Coronary Artery Dissection and Cardiogenic Shock with Extracorporeal Membrane Oxygenation Assisted Recovery in a 30-Year-Old Patientncbi.nlm.nih.gov
78. Pathophysiology, Diagnosis and Treatment of Spontaneous Coronary Artery Dissection in Peripartum Womenncbi.nlm.nih.gov
79. Spontaneous coronary artery dissection ‘storm’ in post-partum: a case report - PMCpmc.ncbi.nlm.nih.gov
80. [Peripartum spontaneous coronary artery dissection: a case report] - PubMedpubmed.ncbi.nlm.nih.gov
81. A case of postpartum spontaneous coronary artery dissection - PMCpmc.ncbi.nlm.nih.gov
82. Hold the Nitro: Acetylcholine Provocation Testing for Coronary Vasospasmncbi.nlm.nih.gov
83. Paroxysmal Atrial Fibrillation during Spasm Provocation Test with Acetylcholine: Clinical Characteristics of Patients and Effect on Coronary Microvascular Function Measurementsncbi.nlm.nih.gov
84. Featureacc.org
85. Impact of Nitroglycerin Administration on Acetylcholine Provocation Testing in Angina With Nonobstructive Coronary Arteriesncbi.nlm.nih.gov
86. Diagnostic accuracy of coronary CT angiography versus invasive coronary angiography for detecting coronary artery disease: a systematic review and Bayesian meta-analysis - PubMedpubmed.ncbi.nlm.nih.gov
87. Coronary CT angiography-guided management of patients with stable chest pain: 10-year outcomes from the SCOT-HEART randomised controlled trial in Scotland - The Lancetthelancet.com
88. Coronary CT Angiography and 5-Year Risk of Myocardial Infarctionnejm.org
89. CT coronary angiography in patients with suspected angina due to coronary heart disease (SCOT-HEART): an open-label, parallel-group, multicentre trial - The Lancetthelancet.com
90. Fractional flow reserve versus angiography for guidance of PCI in patients with multivessel coronary artery disease (FAME): 5-year follow-up of a randomised controlled trial - The Lancetthelancet.com
91. Comparing the adverse clinical outcomes associated with fraction flow reserve-guided versus angiography-guided percutaneous coronary intervention: a systematic review and meta-analysis of randomized controlled trialsncbi.nlm.nih.gov
92. Development and Validation of the American Heart Association’s PREVENT Equationsahajournals.org
93. American Heart Association PREVENTTM Equations Frequently Asked Questions •professional.heart.org
94. PREVENT Equations: A New Era in Cardiovascular Disease Risk Assessmentahajournals.org
95. AHA PREVENT CVD Risk Calculatorendocrine.plus
96. CVD Risk Estimator Plus - American College of Cardiologyacc.org
97. Development and Validation of AHA’s PREVENT Equations - American College of Cardiologyacc.org
98. Coronary Artery Calcium Score as a Graded Decision Toolncbi.nlm.nih.gov
99. Coronary Artery Calcium Is a Common Finding in Older Adultsaafp.org
100. Beyond Traditional Risk Calculators: The Expanding Role of Coronary Artery Calcium Scoring in Preventive Cardiologyncbi.nlm.nih.gov
101. USPSTF: Insufficient Evidence to Support CAC Score, hsCRP, or ABI for Risk Assessmenttctmd.com
102. Lipoprotein(a) Management Simplified: The National Lipid Association Lipid Simplified Series - National Lipid Associationlipid.org
103. New 2026 Dyslipidemia Guidelines Recommend Lipoprotein(a) Testing and Earlier Detection of Inherited Riskfamilyheart.org
104. Rationale for the routine screening of Lipoprotein(a) in cardiovascular risk assessmentacademic.oup.com
105. Intraindividual Lp(a)-Variability in a Real-World Settingncbi.nlm.nih.gov
106. Consensus and guidelines on lipoprotein(a) - Seeing the forest through the trees - PMCpmc.ncbi.nlm.nih.gov
107. Expert Insights: Lp(a) and ApoB in the 2026 Dyslipidemia Guidelineshcplive.com
108. Clinical Impact of Reporting Coronary Artery Calcium Scores of Non-Gated Chest Computed Tomography on Statin Managementncbi.nlm.nih.gov
109. Implications of the 2026 ACC/AHA/Multisociety Dyslipidemia Guideline for Lipid Management in Vascular Disease - American College of Cardiologyacc.org
110. New ACC/AHA Dyslipidemia Guidelines Emphasize Earlier Intervention and Return to LDL-C Targetspatientcareonline.com
111. Prioritizing Healthacc.org
112. ACC, AHA Release New Clinical Guideline For Managing Dyslipidemia - American College of Cardiologyacc.org
113. Dyslipidemia Management: ACC/AHA 2026 Guideline Summaryreference.medscape.com
114. Insights into the 2025 ESC focused update on the management of dyslipidemias - Revista Española de Cardiología (English Edition)revespcardiol.org
115. ESC 2025 Updates Dyslipidaemia Guidelinesmedscape.com
116. What is new in the “2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias”escardio.org
117. Dyslipidemia: ESC/EAS 2025 Guideline Expert Insightreference.medscape.com
118. Antiplatelet therapy after percutaneous coronary interventioneurointervention.pcronline.com
119. Timing, Selection, Modulation, and Duration of P2Y12 Inhibitors for Patients With Acute Coronary Syndromes Undergoing PCIjacc.org
120. Demystifying Antiplatelet Therapy Duration Following Percutaneous Coronary Intervention - American College of Cardiologyacc.org
121. The Emory-Gruentzig Days—Birth of a New Fieldncbi.nlm.nih.gov
122. History of Balloon Angioplasty and Its Impactconceptmedical.com
123. Julio Palmazen.wikipedia.org
124. Benefit of Drug-eluting Coronary Stents in Reducing In-stent Restenosisuscjournal.com
125. DRUG ELUTING STENT FOR DIABETIC PATIENTS IN CORONARY ARTERY DISEASE TREATMENTclinicaltrials.gov
126. In-stent restenosis of drug-eluting stents: clinical presentation and outcomes in a real-world scenariotehj.springeropen.com
127. Selecting conduits for coronary artery bypass grafting: caution regarding the right internal mammary arteryoaepublish.com
128. A Complex Left Internal Mammary Artery Interventionncbi.nlm.nih.gov
129. CABG Graft Types: Arteries, Veins And Patency - Acibadem Hospitals Groupacibademinternational.com
130. Long-term (5 to 12 years) serial studies of internal mammary artery and saphenous vein coronary bypass grafts - ScienceDirectsciencedirect.com
131. Consensus statement—graft treatment in cardiovascular bypass graft surgeryncbi.nlm.nih.gov
132. In-Stent Restenosis in the Drug-Eluting Stent Erajacc.org
133. Comparative Efficacy and Safety of Coronary Artery Bypass Grafts: Insights from a Systematic Review and Meta-Analysismedrxiv.org
134. ACC/ACEP/AHA/SCAI Management of Patients With Acute Coronary Syndromes Guideline Summary - Guideline Centralguidelinecentral.com
135. ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction—Executive Summaryahajournals.org
136. 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarctionahajournals.org
137. Guideline 14.3anzcor.org
138. STEMI: Fibrinolysis, Indications, Contraindications and Rescue PCI · The Cardiovascularecgwaves.com
139. D-14jscai.org
140. Diagnosis, risk stratification, and early management of non-ST-segment elevation acute coronary syndromeeurointervention.pcronline.com
141. Timing of invasive strategy in non-ST-elevation acute coronary syndrome: a meta-analysis of randomized controlled trialsacademic.oup.com
142. Very early invasive strategy in higher risk non-ST-elevation acute coronary syndrome: the RAPID NSTEMI trialncbi.nlm.nih.gov
143. The 2025 ACC/AHA Guideline for Acute Coronary Syndromes: A View From Down Underjacc.org
144. Acute Coronary Syndromes: ESC 2023 Guideline Summaryreference.medscape.com
145. STEMI treatment in areas remote from primary PCI centreseurointervention.pcronline.com
146. Ischemic Cardiomyopathy and Heart Failure After Acute Myocardial Infarctionlink.springer.com
147. Evolution of Left Ventricular Ejection Fraction After Acute Myocardial Infarctionahajournals.org
148. Trajectories and determinants of left ventricular ejection fraction after the first myocardial infarction in the current era of primary coronary interventionsncbi.nlm.nih.gov
149. Predictors and prognostic impact of left ventricular ejection fraction trajectories in patients with ST-segment elevation myocardial infarctionncbi.nlm.nih.gov
150. Prognosis in patients with low left ventricular ejection fraction after myocardial infarction. Importance of exercise capacity - PubMedpubmed.ncbi.nlm.nih.gov
151. Influence of standard modifiable risk factors on ventricular tachycardia after myocardial infarctionncbi.nlm.nih.gov
152. Incidence and Risk Factors for Ventricular Arrhythmias in Patients With Acute Myocardial Infarction Presenting to the Emergency Departmentncbi.nlm.nih.gov
153. Arrhythmias and Sudden Cardiac Death After Myocardial Infarction - ScienceDirectsciencedirect.com
154. Incidence and Risk Factors for Ventricular Arrhythmias in Patients With Acute Myocardial Infarction Presenting to the Emergency Department - PMCpmc.ncbi.nlm.nih.gov
155. Risk Stratification of Sudden Cardiac Death After Acute Myocardial Infarctionncbi.nlm.nih.gov
156. Anterolateral Papillary Muscle Rupture: A Rare Complication of Myocardial Infarctionjacc.org
157. Report on Rare Complication Post Silent Myocardial Infarction: Ventricular Septal Rupturencbi.nlm.nih.gov
158. Untangling Mechanical Complications of Acute Myocardial Infarctionjacc.org
159. Septal occlusion devices and methodsimage-ppubs.uspto.gov
160. Mechanical Complications of Acute Myocardial Infarction: A Scientific Statement From the American Heart Associationahajournals.org
161. Mechanical Complications of Myocardial Infarction - PubMedpubmed.ncbi.nlm.nih.gov
162. Two-year clinical outcome of patients with mildly reduced ejection fraction after acute myocardial infarction: insights from the prospective KAMIR-NIH Registryncbi.nlm.nih.gov
163. Management strategies in patients at high risk of sudden cardiac death following myocardial infarction - PubMedpubmed.ncbi.nlm.nih.gov
164. Cardiac Rehabilitation as Secondary Prevention - AHCPR Quick Reference Guides - NCBI Bookshelfncbi.nlm.nih.gov
165. Benefits of Cardiac Rehabilitation: Mechanisms to Restore Function and Clinical Impactahajournals.org
166. Part 1—Cardiac Rehabilitation After an Acute Myocardial Infarction: Four Phases of the Programme—Where Do We Stand?ncbi.nlm.nih.gov
167. Women face barriers in accessing, participating in cardiac rehab despite proven benefitsmedicalxpress.com
168. The Effectiveness of Cardiac Rehabilitation Programs in Improving Cardiovascular Outcomes: Systematic Review and Meta-Analysisncbi.nlm.nih.gov
169. Cardiac rehabilitation meta-analysis of trials in patients with coronary heart disease using individual participant data (CaReMATCH): Project protocol - PMCpmc.ncbi.nlm.nih.gov
170. The Effect of Cardiac Rehabilitation on Health-Related Quality of Life in Patients With Coronary Artery Disease: A Meta-analysis - ScienceDirectsciencedirect.com
171. Effect of Cardiac Rehabilitation Dose on Mortality and Morbidity: A Systematic Review and Meta-regression Analysis - ScienceDirectsciencedirect.com
172. Cardiac Rehabilitation in the Modern Era: Evidence, Equity, and Evolving Delivery Models Across the Cardiovascular Spectrummdpi.com
173. Reengineering Cardiac Rehabilitation for Women: From Access to Equity - PMCpmc.ncbi.nlm.nih.gov
174. Women’s Cardiac Rehabilitation Barriers: Results of the International Council of Cardiovascular Prevention and Rehabilitation’s First Global Assessment - ScienceDirectsciencedirect.com
175. Cardiac Rehabilitation for Women: A Systematic Review of Barriers and Solutions - Mayo Clinic Proceedingsmayoclinicproceedings.org
176. Cardiac Rehab Infographic 508millionhearts.hhs.gov
177. Cardiac Rehabilitation in Patients After Coronary Artery Bypass Grafting: Core Components and Long-Term Follow-Upncbi.nlm.nih.gov
178. NCA - Cardiac Rehabilitation Programs (CAG-00089R) - Decision Memocms.gov
179. Cardiac Rehabilitation for Patients With Heart Failure: JACC Expert Paneljacc.org
180. Physical and Mental Components of Quality of Life after a Cardiac Rehabilitation Intervention: A Systematic Review and Meta-Analysisncbi.nlm.nih.gov
181. Global, regional and national burden of ischemic heart disease and its attributable risk factors from 1990 to 2021: a systematic analysis of the Global Burden of Disease study 2021link.springer.com
182. Global ischemic heart disease burden attributable to environmental risk factors, 1990–2021: an Age-Period-Cohort analysisncbi.nlm.nih.gov
183. Global, Regional, and National Burden of Cardiovascular Disease, 1990-2021: Results From the 2021 Global Burden of Disease Studycureus.com
184. Global Trends in Ischemic Heart Disease-Related Mortality From 2000 to 2019jacc.org
185. Global burden of cardiovascular diseases and risks, 1990-2022healthdata.org
186. Global, regional, and national burden of ischaemic heart disease from 1990 to 2021: a comprehensive analysis based on the Global Burden of Disease study 2021 — JOGHjogh.org
187. Trends and predictive research on the global burden of ischemic heart disease from 1990 to 2021: an analysis of the Global Burden of Disease study 2021ncbi.nlm.nih.gov
188. Coronary heart disease mortality is decreasing in Argentina, and Colombia, but keeps increasing in Mexico: a time trend studyncbi.nlm.nih.gov
189. Cardiovascular disease declines in rich countries but poor countries suffer moretheconversation.com
190. Cardiovascular mortality trends in Switzerland 1995–2018ncbi.nlm.nih.gov
191. Acute coronary syndromes in low- and middle-income countries: Moving forward - ScienceDirectsciencedirect.com
192. 1 WORLD HEART REPORT 2023 CONFRONTING THE WORLD’S NUMBER ONE KILLERworld-heart-federation.org
193. Global, Regional, and National Burden of Cardiovascular Diseases and Risk Factors in 204 Countries and Territories, 1990-2023jacc.org
194. Burden of non-rheumatic valvular heart disease globally and in China from 1990 to 2021: a systematic analysis for the global burden of disease study 2021ncbi.nlm.nih.gov
195. Global, regional, and national burden of ischemic heart disease in young and middle-aged population from 1990 to 2021nature.com
196. Global trends in the burden of ischemic heart disease attributable to smoking from 1990 to 2021: A systematic analysis of the Global Burden of Disease Study 2021ncbi.nlm.nih.gov
197. Global Epidemiology of Ischemic Heart Disease: Results from the Global Burden of Disease Studyncbi.nlm.nih.gov
198. Gender differences in coronary heart disease - PubMedpubmed.ncbi.nlm.nih.gov
199. Gender Disparities in Ischemic Heart Disease Management: Underdiagnosis in Women and Differences in Treatmentncbi.nlm.nih.gov
200. A comprehensive analysis of female participation in cardiovascular trials involving the WCN investigator networkncbi.nlm.nih.gov
201. Socioeconomic Status and Cardiovascular Outcomesahajournals.org
202. Neighbourhood Socioeconomics Status Predicts Non-Cardiovascular Mortality in Cardiac Patients with Access to Universal Health Carencbi.nlm.nih.gov
203. Variation in rates of fatal coronary heart disease by neighborhood socioeconomic status: the atherosclerosis risk in communities surveillance (1992-2002) - PubMedpubmed.ncbi.nlm.nih.gov
204. Bridging the Gap: Socioeconomic Disparities in Coronary Heart Disease Knowledge, Awareness, and Lifestyle Practices in Bangladeshmedrxiv.org
205. Racial and Socioeconomic Determinants of Cardiovascular Health: A Comprehensive Review - PMCpmc.ncbi.nlm.nih.gov
206. Gender Disparities in Ischemic Heart Disease Management: Underdiagnosis in Women and Differences in Treatment - PMCpmc.ncbi.nlm.nih.gov
207. Understanding sex differences in cardiovascular medicine: a plea for combining clinical trials with real-world datancbi.nlm.nih.gov
208. The Association between Neighborhood Socioeconomic Status and Clinical Outcomes among Patients 1 Year after Hospitalization for Cardiovascular Disease - PMCpmc.ncbi.nlm.nih.gov
209. TOBACCO & CORONARY HEART DISEASE - IRISiris.who.int
210. Cardiovascular risk of smoking and benefits of smoking cessation - Gallucci - Journal of Thoracic Diseasejtd.amegroups.org
211. Longitudinal Associations of Smoke-free Policies and Incident Cardiovascular Disease: The Coronary Artery Risk Development in Young Adults (CARDIA) Study - PMCpmc.ncbi.nlm.nih.gov
212. Salt Reduction to Prevent Hypertension and Cardiovascular Disease: JACC State-of-the-Art Reviewjacc.org
213. Projected Effect of Dietary Salt Reductions on Future Cardiovascular Diseasenejm.org
214. Reduced dietary salt for the prevention of cardiovascular diseasecochrane.org
215. Role of salt intake in prevention of cardiovascular disease: controversies and challengesnature.com
216. Do Recommendations for the Management of Hypertension Improve Cardiovascular Outcome? The Canadian Experiencencbi.nlm.nih.gov
217. Impact of a rural high blood pressure control program on hypertension control and cardiovascular disease mortality - PubMedpubmed.ncbi.nlm.nih.gov
218. Cost-utility analysis of a national project to reduce hypertension in Israelncbi.nlm.nih.gov
219. Improved Blood Pressure Control to Reduce Cardiovascular Disease Morbidity and Mortality: The Standardized Hypertension Treatment and Prevention Project - PMCpmc.ncbi.nlm.nih.gov
220. Sustained blood pressure control and coronary heart disease, stroke, heart failure, and mortality: An observational analysis of ALLHAT - PMCpmc.ncbi.nlm.nih.gov
221. Blood Pressure Control and Mortality Among US Veterans - PMCpmc.ncbi.nlm.nih.gov
222. Salt Reduction to Prevent Hypertension and Cardiovascular Disease: JACC State-of-the-Art Review - ScienceDirectsciencedirect.com
223. Reduced dietary salt for the prevention of cardiovascular disease - PMCpmc.ncbi.nlm.nih.gov
224. Effect of Salt Substitution on Cardiovascular Events and Deathnejm.org
225. Ischemic myocardial disease as an example of a thrombotic event. A historical note - PubMedpubmed.ncbi.nlm.nih.gov
226. James Bryan Herrick - Hektoen Internationalhekint.org
227. James B. Herricken.wikipedia.org
228. History of Heart Attack: Diagnosis and Understanding « Heart Attack Preventionepi.umn.edu
229. Review of thrombolytic intervention for acute myocardial infarction--is it valuable? - PubMedpubmed.ncbi.nlm.nih.gov
230. Pathophysiology and clinical significance of atherosclerotic plaque ruptureacademic.oup.com
231. Coronary Intervention: History and Current Status - PMCpmc.ncbi.nlm.nih.gov
232. F. Mason Sones Jr.: The Serendipitous Discovery of Coronary Angiography and Its Lasting Impact on Cardiologyncbi.nlm.nih.gov
233. THE MAGNIFICENT CENTURY OF CARDIOTHORACIC SURGERYncbi.nlm.nih.gov
234. The father of coronary artery bypass grafting: René Favaloro and the 50th anniversary of coronary artery bypass grafting - The Journal of Thoracic and Cardiovascular Surgeryjtcvs.org
235. Inception of the coronary stent: a story of successful collaboration between innovative scientists and the biotechnology industryrecintervcardiol.org
236. Rene Favaloro—Father of cardiac bypass surgery - Hektoen Internationalhekint.org
237. Balloon Angioplasty – The Legacy of Andreas Grüntzig, M.D. (1939–1985)ncbi.nlm.nih.gov
238. Official Scientific Statement from the Brazilian Society of Cardiovascular Surgery - The 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization and the 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for Chronic Coronary Diseasencbi.nlm.nih.gov
239. STS/AATS-endorsed rebuttal to 2023 ACC/AHA Chronic Coronary Disease Guideline: A missed opportunity to present accurate and comprehensive revascularization recommendations - The Journal of Thoracic and Cardiovascular Surgeryjtcvs.org
240. Multisociety endorsement of the 2024 European guideline recommendations on coronary revascularizationncbi.nlm.nih.gov
241. 2023 AHA/ACC Clinical Performance and Quality ...ishlt.org
242. Coronary artery calcium scoring in individuals at risk for coronary artery disease: current status and future perspectives - PMCpmc.ncbi.nlm.nih.gov
243. Major Global Coronary Artery Calcium Guidelinesjacc.org
244. Screening for Coronary Heart Disease: Recommendation Statementdx.doi.org
245. Design and Rationale of Lp(a)HORIZON Trial: Assessing the Effect of Lipoprotein(a) Lowering With Pelacarsen on Major Cardiovascular Events in Patients With CVD and Elevated Lp(a) - ScienceDirectsciencedirect.com
246. Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVDclinicaltrials.gov
247. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelinesahajournals.org
248. Multisociety endorsement of the 2024 European guideline recommendations on coronary revascularization - The Journal of Thoracic and Cardiovascular Surgeryjtcvs.org
249. Pelacarsen: Mechanism of action and Lp(a)-lowering effect - Journal of Clinical Lipidologylipidjournal.com